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The clinical utility of most cancer therapies is limited either by the inability to deliver therapeutic 
drug concentrations to the target cancer cells or by severe and harmful toxic effects on normal 
organs and tissues. Different approaches have been attempted to overcome these problems by 
providing “site-specific” delivery of drugs to the affected area using various pharmaceutical 
carriers. Among the different types of nanocarriers used in the delivery of anticancer drugs, 
liposomes have received the most attention. Liposomes are phospholipid bilayer vesicles and 
considered as biocompatible, cause very little or no antigenic, pyrogenic, allergic and toxic 
reactions inside the host. D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), an 
alternative to PEG, is an amphiphilic macromolecule, water-soluble derivative of natural vitamin 
E. It is an effective emulsifier in nanotechnology for biomedical applications. Co-administration 
of TPGS can enhance the solubility, cellular internalization, inhibit P-glycoprotein mediated 
multi-drug efflux transport system, and increase the oral bioavailability of various anticancer 
drugs. Docetaxel (DTX) has been known to have excellent therapeutic effects for a wide 
spectrum of cancers such as breast cancer, ovarian cancer and head and neck cancer. Herceptin is 
a monoclonal antibody which targets and binds with HER2 receptors on the surface of the breast 
cancer cells. In this study we have prepared docetaxel loaded herceptin conjugated liposomes 
with TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate) coating and compared their 
effect with non-conjugated TPGS coated liposomes and Taxotere® for targeted chemotherapy on 
breast cancer cells. To facilitate the conjugation of herceptin, carboxyl group terminated TPGS 
has been synthesized and used in the preparation of herceptin conjugated liposomes. Docetaxel 
or Coumarin-6 loaded liposomes were prepared by solvent injection method and characterized 
for their size and size distribution, surface charge, surface chemistry and drug/dye encapsulation 
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efficiency and in vitro drug release profile. SKBR-3 cells were employed as an in vitro model for 
HER2 positive breast cancer and assessed for their cellular uptake and cytotoxicity of the 
coumarin-6 and docetaxel loaded immunoliposomes respectively. The particle size of these 
liposomes ranged between 140-220 nm. High resolution field emission transmission electron 
microscopy (FETEM) was used to visualize the morphology and surface coating of TPGS on the 
liposomes. X-ray photoelectron spectroscopy (XPS) and FTIR data confirmed the presence of 
herceptin conjugated on the surface of liposomes. Differential scanning Calorimetry was used to 
investigate the molecular arrangement of TPGS-COOH and docetaxel with the lipid bilayer. In 
vitro cellular uptake was studied by confocal microscopy and higher uptake was observed with 
immunoliposomes. The IC50 value, which is the drug concentration needed to kill 50 % cells in 
a designated time period, was found to be 20.23 ± 1.95, 3.74 ± 0.98, 0.08 ± 0.4 μg/ml for the 
Taxotere®, TPGS coated liposomes and herceptin conjugated liposomes respectively after 24 h 
incubation with SKBR-3 cells. In vivo PK experiments showed that i.v. administration of 
herceptin conjugated liposomes achieves 1.9 and 10 times longer half-life respectively than PEG 
coated liposomes and Taxotere®. The relative bioavailability of docetaxel was increased by 3.47 
fold by the herceptin conjugated liposomes. Thus the herceptin conjugated Vitamin E TPGS 
coated liposomes showed greater potential for sustained and targeted chemotherapy in the 
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CHAPTER 1: INTRODUCTION 
1.1. Background 
Chemotherapy is one of the most important treatments currently available for the different types 
of cancer. Since the discovery of chemotherapeutic drugs for cancer, many challenges have been 
raised due to the systemic toxicity and adverse side effects caused by these drugs (Feng and 
Chien, 2003). To address this issue many novel drug carrier systems which have the ability of 
controlled and targeted/site-specific drug delivery to the cancer cells have been developed. The 
platform for these carrier systems was provided by the nanotechnology concept and consists of 
wide variety of particles such as micelles, liposomes, solid lipid nanoparticles and nanoparticles 
of biodegradable polymers (Muthu and Feng, 2010). Liposomes are the lipid bilayer vesicles, 
composed of either a single bilayer (SLV) or multiple layered vesicles (MLV) and discovered 40 
years ago by Bangham et al. in 1965 (Bangham et al., 1965). Since then they have become very 
versatile and has been used as drug carriers for various diseases including cancer (Sharma et al., 
2006). Liposomes can be seen as the simplest artificial biological cells, which have great 
potential applications in drug delivery, gene therapy, molecular imaging and artificial blood as 
well as to be used as a model biological cell and cell membrane (Muthu and Feng, 2010). 
Liposomes have various advantages over other drug carrier systems. They have no 
biocompatibility problem and provide desired adhesion to the biological cells. Liposomes used in 
drug delivery applications may vary in size for about less than 200 nm and composed of 
phospholipids, which are amphiphilic in nature to encapsulate water soluble hydrophilic drugs in 
the core and hydrophobic drugs in their bilayer region. One of the main problems associated with 
these liposomes is their poor stability and cholesterol is incorporated into the liposomal 
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membrane to increase their mechanical strength (Torchilin, 2008) and control the release of the 
encapsulated drugs. With the help of such drug delivery systems, the chemotherapeutic drugs can 
be reached to the cancer cells through 1) Passive targeting by enhanced permeation and retention 
(EPR) effect of the leaky vasculature of tumors which allows these nanocarriers to be 
accumulated in the tumor and 2) Active targeting with ligand conjugation towards particular cell 
surface markers on the cancer cells (Danhier et al., 2010). Active targeting has always proven to 
be promising approach for better therapeutic efficacy than passive targeting.  
Antibody conjugated liposomes or immunoliposomes efficiently targets the drug towards desired 
tissue or organ. These targeted liposomes along with surface attached ligand were capable of 
recognizing and binding towards specific molecular targets on the cancer cells. Herceptin® 
(trastuzumab) is a humanized IgG1 monoclonal antibody approved by US FDA for the treatment 
of human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancers (Liu 
et al., 2010). HER2 is a member of the EGF receptor (EGFR) family, which is a receptor 
tyrosine specific protein kinase family consisting of four semi homologous receptors EGFR, 
HER2, HER3 and HER4. These receptors interact with several ligand and generate intracellular 
signals either by homodimerization or forming heterodimer pairs. The EGFR family is thought to 
play a primary role in the control of epithelial cell proliferation and mutations affecting EGFR 
activity can result in cancer (Sun and Feng, 2009). It is known that HER2 is amplified at 20-30% 
in human invasive breast cancer (Steinhauser et al., 2006). Therefore targeting HER2 as a 
potential receptor is the key therapeutic strategy for HER2-overexpressing breast cancer cells. 
Conjugation of herceptin on drug loaded liposomes will elicit synergistic antitumor effects. 
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D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or simply TPGS) is a 
PEGylated vitamin E, which has greatly improved the pharmaceutical properties of vitamin E 
and thus has been widely applied in the food and drug industry.  TPGS was prepared from the 
esterification of D-alpha-tocopheryl acid succinate and PEG 1000. It is an amphiphilic vitamin E 
and quite stable under normal conditions without hydrolysis. Owing to its hydrophilic-liphophilic 
balance (HLB) value of about 13, TPGS has excellent water solubility and it is suitable to serve 
as an effective surfactant which can emulsify hydrophobic molecules (Varma and Panchagnula, 
2005b; Wu and Hopkins, 1999). The co-administration of TPGS has been shown to enhance the 
solubility, inhibit P-glycoprotein mediated multi-drug resistance, and increase the oral 
bioavailability of anti-cancer drugs (Boudreaux et al., 1993; Dintaman and Silverman, 1999; Mu 
et al., 2005). We have reported TPGS-doxorubicin conjugate as a novel prodrug which enhanced 
the therapeutic potential and reduced the systemic side effects of the drug (Anbharasi et al., 
2010; Cao and Feng, 2008). Additionally, we studied TPGS as an emulsifier in the preparation of 
poly (D, L, lactide-co-glycolide) (PLGA) nanoparticles (Mu and Feng, 2003b), and as a 
component of new biodegradable copolymer polylactide-TPGS (PLA-TPGS) for nanoparticle 
formulation of anti-cancer drugs(Zhang and Feng, 2006). As an effective emulsifier, TPGS has 
greatly enhanced the performance of nanoparticles, resulting in much higher emulsification 
efficiency (67 times higher than polyvinyl alcohol), drug encapsulation efficiency (up to 100%) 
(Mu and Feng, 2002), cellular uptake, and in vitro cancer cell cytotoxicity, and more desirable in 
vivo pharmacokinetics (up to 360 h effective treatment for one shot i.v. administration) (Win and 
Feng, 2006). Also, we have creatively recognized the marvelous advantageous of TPGS 
derivative (TPGS2000) as an effective composition of docetaxel loaded micelles for synergistic 
effect (Mi et al., 2011; Mu et al., 2005). 
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We used Docetaxel (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl-paclitaxel) as a model 
anticancer drug in this study. It is a semi-synthetic derivative of the taxoid family of anti-
neoplastic agents (Bissery et al., 1991). Pre-clinical studies demonstrated that docetaxel had 
several advantages over paclitaxel (Jones, 2006). Compared with paclitaxel, docetaxel showed 
wider cell-cycle bioactivity, greater affinity for the β-tubulin binding site and greater uptake with 
slower efflux from the tumor cells, resulting in longer intracellular retention time and higher 
intracellular concentrations (Brunsvig et al., 2007; Riou et al., 1992; Riou et al., 1994). It was  
reported  that  docetaxel  exhibited  12-fold  cytotoxic  activity  than  paclitaxel  and docetaxel 
showed higher growth inhibition in human epidermal growth receptor (HER2) positive cells 
compared to paclitaxel (Hanauske et al., 1994; Lavelle et al., 1995). 
TPGS coated liposomes was first introduced by Wang et al. in 2005 (Wang, 2005). Doxorubicin 
loaded TPGS coated liposomes has been developed and the pharmacokinetic results revealed that 
these liposomes have 24 h longer circulation time than PEG coated liposomes. It has been 
recently studied that TPGS containing liposomes showed improvement in the permeation of 
dextran through Caco-2 cells (Transwell® model) without any cytotoxicity effects (Parmentier et 
al., 2011; Parmentier et al., 2010). They focused on the oral drug delivery for better permeability 
and stability across the gastro-intestinal tract. We have showed recently that TPGS coated 
liposomes has better physicochemical properties for tumor targeting compared to PEG coated 
liposomes (Muthu et al., 2011). Thus it leads to a long way to characterize and decipher the 




1.2. Objectives and Thesis Organization 
Our aim is to prepare docetaxel loaded herceptin conjugated liposomes via TPGS coating and to 
compare the effect with the clinical Taxotere® (Docetaxel formulated in polysorbate 80), which 
causes side effects inspite of higher patient response than Taxol® (Paclitaxel formulated in 
Cremophor EL). We have already used carboxyl group activated TPGS (TPGS-COOH) for the 
conjugation of herceptin with polymeric nanoparticles (Sun and Feng, 2009). In this study we 
used one similar for the preparation of herceptin conjugated liposomes. Following the 
preparation and characterization of these liposomes, a series of cell works involving cancer cell 
lines as well as animal models are included to evaluate the formulation before it is tested in 
clinical trials. 
There are six chapters which formed the framework of this thesis. The first chapter gave a 
general background and concepts of developing liposomal nanocarriers for targeted cancer 
chemotherapy. In Chapter 2, a detailed literature review on cancer and its causes, current 
treatments available, problems faced in conventional chemotherapy and the concept of different 
drug delivery formulations were provided. Then, Chapter 3 presents the preparation and 
characterization vitamin E TPGS coated and herceptin conjugated liposomes. The liposomes 
were prepared by solvent injection method and characterized by various state-of-art analytical 
instruments. Following that, Chapter 4 includes the in vitro cellular study for the liposomes 
formulations. Human breast adenocarcinoma SK-BR-3 cell lines which over expresses HER2 
receptors was employed to assess cellular uptake as well as to evaluate the cell viability of the 
liposomes formulations which is done in close comparison with Taxotere®. In Chapter 5, in vivo 
pharmacokinetics using Sprague-Dawley (SD) rats is investigated to further confirm the 
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advantages of the herceptin conjugated liposomes versus the commercial drug. Finally, 
conclusion and suggestions for future work are provided in Chapter 6, followed by the reference 
papers cited in this thesis. 
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CHAPTER 2:  LITERATURE REVIEW 
2.1. Cancer and its facts 
Among most of the diseases, the leading cause of death globally is cancer. According to US 
National Cancer Institute, cancer is defined as diseases in which abnormal cells undergo 
uncontrolled growth (or mitosis) and have the ability to invade other tissues of the body through 
blood circulation and lymphatic systems.1 Unlike normal cells, cancer cells do not stop 
reproducing after they have doubled 50 or 60 times. This means that a cancer cell will go on and 
on and on doubling. The cancer cells may be able to stop themselves self destructing. Or they 
may self destruct more slowly than they reproduce, so that their numbers continue to increase.2 
Eventually a tumour is formed that is made up of billions of copies of the original cancerous cell. 
One among three people will be diagnosed with cancer during their lifetime, and new cases of 
cancer are increasing at a rate of 1% per year.3 Currently, more than 200 types of cancer have 
been discovered, with probability of getting cancer being distinct in different types of tissues or 
organs, even within the same individuals. 
2.2. Cancer prevalence and its causes 
Cancer may affect people at all ages but in most cases the number of cancer patient increases 
with age. All cancers are almost caused by the abnormalities in the genetic material of the 
transformed cells. These genetic abnormalities in cancer affect 2 types of genes namely Tumor 








In cancer, the oncogenes are activated and the tumor suppressor genes are inactivated. Here, the 
oncogenes are responsible for the hyperactive growth and division of the cancer cells, to adjust in 
different environments and cause programmed cell death. Now the Tumor suppressor genes are 
responsible for the loss in control over the cell cycle, adhesion with other tissues and interaction 
with the immune cells. The two wide factors that cause the cancerous cells are the external 
factors and the internal factors. The external factors include  
 Tobacco smoking  
 Chemicals  
 Radiation  
 Infections  
 Alcohol  
 Poor diet  
 Lack of physical activity or overweight 
The internal factors include  
 Inherited mutations  
 Hormones 
 Growing older 
 Immune conditions 
These factors are said to be the most common risk factors for cancer. Many of these risk factors 
can be avoided and several of these factors may act together to cause normal cells to become  
cancerous. The chemicals that cause cancer are called carcinogens and those chemicals that 
cause cancer through mutations in DNA are called mutagens. All mutagens are carcinogens, but 
all carcinogens are not mutagens. They cause rapid rates of mitosis of the cells and thus 
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inactivate the enzyme that does the DNA repair. One of the most important carcinogens is 
tobacco. Smoking and its related disease remains the world’s most preventable cause of death 
and so is the cancer also. According to National Cancer Institute (NCI), each year, more than 
180,000 Americans die from cancer that is related to tobacco use. Tobacco smoking accounts for 
at least 30 % of all cancer deaths and 87 % of lung cancer deaths. The risk of developing lung 
cancer is about 23 times higher in male smokers and 13 times higher in female smokers 
compared to non- smokers.4 Also, quitting smoking substantially decreases the risk of cancer. 
Prolonged exposure of radiation such as ultra violet radiation from the sun, sun lamps and 
tanning booths causes early ageing of the skin and skin damage that can lead to skin cancer. 
Ionizing radiation usually causes cell damage that leads to cancer. This kind of radiation comes 
from the rays that enter the earth’s atmosphere from outer space, radioactive fallout, radon gas, 
x-rays and other sources. The radioactive fallout can come from accidents at nuclear power 
plants or from the production, testing or use of atomic weapons. People exposed to fallout may 
have an increased risk of cancer, especially leukemia and cancer of thyroid, breast, lung and 
stomach. Radon is a radioactive gas that we cannot see, smell or taste. People who work in mines 
may be exposed to radon. People exposed to radon are at increased risk of lung cancer. The risk 
of cancer from low dose x-rays is very small and that from the radiation therapy is slightly 
higher. Being infected with certain viruses or bacteria may increase the risk of developing 
cancer. HPV (Human papillomavirus) infection is the main cause of cervical cancer. It also may 
be a risk factor for other types of cancer. Hepatitis B and Hepatitis C viruses can cause liver 





Infection with HTLV-1 (Human T-cell leukemia/lymphoma virus) increases a person’s risk of 
developing lymphoma and leukemia. HIV (Human Immunodeficiency Virus) is the virus that 
causes AIDS. People who possess HIV have a greater risk of having cancer such as lymphoma 
and a rare cancer called ‘Kaposi’s sarcoma’. EBV (Epstein – Barr virus) infection can cause 
lymphoma. Human herpes virus 8 (HHV8) is a risk factor for Kaposi’s sarcoma. Helicobacter 
pylori bacteria can cause stomach ulcers. It can also cause stomach cancer and lymphoma in 
stomach lining. The viruses are responsible for about 15% of the cancers worldwide. The 
hormonal imbalance causes cancer due to the hormones acting in the same manner as the non-
mutagenic carcinogens. Hormones may increase the risk of breast cancer, heart attack, stroke or 
blood clot. Diethylsilbestrol (DES), a form of estrogen, was given to pregnant woman in the 
United States between about 1940 and 1971. Woman who took DES during their pregnancy may 
have a slightly higher risk of developing breast cancer. Their daughters have an increased risk of 
developing a rare type of cancer of cervix. The effects on their sons are under study. The 
immune system malfunction also causes cancer to a greater extent and heredity causes cancer as 
well. Most cancers develop because of changes (mutations) in genes. A normal cell may become 
a cancer cell after a series of gene changes occur. Tobacco use, certain viruses, or other factors in 
a person's lifestyle or environment can cause such changes in certain types of cells. Some gene 
changes that increase the risk of cancer are passed from parent to child. These changes are 
present at birth in all cells of the body. It is uncommon for cancer to run in a family. However, 
certain types of cancer do occur more often in some families than in the rest of the population. 
For example, melanoma and cancers of the breast, ovary, prostate, and colon sometimes run in 
families. Several cases of the same cancer type in a family may be linked to inherited gene 
changes, which may increase the chance of developing cancers. However, environmental factors 
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may also be involved. Most of the time, multiple cases of cancer in a family are just a matter of 
chance. Having more than two drinks each day for many years may increase the chance of 
developing cancers of the mouth, throat, esophagus, larynx, liver, and breast. The risk increases 
with the amount of alcohol that a person drinks. For most of these cancers, the risk is higher for a 
drinker who uses tobacco. People who have a poor diet, do not have enough physical activity, or 
are overweight may be at increased risk of several types of cancer. For example, studies suggest 
that people whose diet is high in fat have an increased risk of cancers of the colon, uterus, and 
prostate. Lack of physical activity and being overweight are risk factors for cancers of the breast, 
colon, esophagus, kidney, and uterus.  
2.3. Cancer Treatments and their Limitations 
Some of the common treatments available to cancer are surgery, chemotherapy, radiation 
therapy, immunotherapy, monoclonal antibody therapy and gene therapy. Each method has its 
advantages and disadvantages, and depends on the physiology of the individuals as an effective 
treatment strategy in one person may fail in another. Surgical removal of tumors from cancer 
patients is usually the first consideration in cancer treatment. This is especially the case when the 
tumor size is large and starts to damage the functionality of the tissues or organs surrounding it. 
Unfortunately, surgery has a few drawbacks.  Firstly, surgery is an invasive method of cancer 
treatment with potential wound infection. And, it can only be done when the tumor is sufficiently 
large to be removed. Secondly, for patients with medical history such as haemophilia, it may not 
be advisable to undergo such procedure.  Thirdly, surgery can sometimes trigger the metastasis 
of tumor, even it is successfully removed (Weiss and DeVita, 1979). Radiotherapy is also 
another primary treatment modality in which ionizing radiation is used to destroy cancerous 
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tissues. However, this method is only applicable to localized tumor such as prostate cancer and 
recurrence of cancer also occurs in some patients (De Riese et al., 2002). Therefore, a 
combination of surgery and radiotherapy will usually have immediate local response in terms of 
tumor cell death.  But, it is not effective in controlling re-growth and metastatic secondary tumor 
growth (Camphausen et al., 2001; Chen et al., 2006). Meanwhile, hormone therapy is restricted 
to organ-confined cancers such as breast and prostate cancer and long term treatment of 
metastatic tumor using this method is unlikely (Corral et al., 1996; De Riese et al., 2002). 
Immunotherapy, by stimulating the immune system through general or specific immune 
enhancement, only renders a low success rate to patients. Chemotherapy, often used in 
combination with other treatment modalities, is the treatment of diseases or cancers using 
chemical agents or antineoplastic drugs. These chemical agents, which are usually very toxic, 
can inhibit the tumor growth. But they can also kill the normal, healthy cells, and thus bring 
unwanted side effects. Nowadays, various kinds of anticancer drugs are available in the market. 
Some examples include paclitaxel, chlorambucil, fluorouracil, methotrexate and doxorubicin. 
The cytotoxic mechanisms of chemotherapeutic agents differ from each other, depending on the 
nature of the drugs, the molecular structure, physicochemical properties and the sites of actions 
in the body. 
2.3.1. Problems in Chemotherapy 
The common problem with most antineoplastic drugs is their poor solubility in aqueous phase.  
Paclitaxel, for example, is highly hydrophobic with a solubility of less than 0.5 mg/L in water 
(Feng and Chien, 2003; Hennenfent and Govindan, 2006). This is not desirable  because  the  
drug  has  to  be  dissolved  in  blood,  with  water  as  the  major component,  in  order  to  be  
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transported  to  the  cancer  cells.  Therefore, solubilizers or adjuvants are necessary to increase 
the solubility of anticancer drugs. It is also this reason why most of the current commercial drug 
formulations are only able to be administered intravenously (infusion).  Routes of administration 
are thus limited.  In  Taxol®,  the commercial  formulation  for  paclitaxel,  Cremophor  EL  is  
applied  as  the  adjuvant (Hennenfent and Govindan, 2006; Xie et al., 2007). Cremophor EL, a 
nonionic surfactant, consists of polyethoxylated   castor   oil and dehydrated ethanol (1:1 v/v).  
Although Cremophor EL is a vehicle for various hydrophobic pharmaceutical agents including 
cyclosporine and diazepam, it has been found to cause serious adverse effects to patients. 
Biologic effects such as hypersensitivity, nephrotoxicity and peripheral neuropathies are believed 
to have associated with the use of Cremophor EL in the formulation (Feng et al., 2007; 
Gelderblom et al., 2001; Theis et al., 1995). Secondly, human body will normally treat most 
anticancer drugs as foreign substances which the body cannot recognize. As a result, the native 
drugs administered into the body will   greatly be   subjected   to   the   degradation   by some   
endogenous   enzymes   or macromolecules which are considered as part of the body natural 
defense mechanism and immune system. The first-pass metabolism is an important process that 
takes place in liver and intestine before the drugs are absorbed into the circulatory system (Feng 
et al., 2007). It is the physiological barrier to be crossed before the drugs can be distributed to 
other parts of the body.   The most common kind of enzyme involved in this degradation of 
drugs is cytochrome P450 (or CYP), mainly located in liver and intestine. CYP is a large family 
of hemoproteins which consists of 18 families and 43 subfamilies and it contributes to nearly 
75% of total metabolic process in human body (Danielson, 2002; Guengerich, 2008; Nelson et 
al., 1993).  It is found on the membrane of endoplasmic reticulum as well as mitochondria.  
However, most members from CYP1, CYP2 and CYP3 families take part in drug metabolism. 
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For instance, almost 80% of administered docetaxel, an anticancer drug popular for its efficacy 
towards various types of cancer, is metabolized by CYP3A4 through hepatic transformation 
(Baker et al., 2006; Bradshaw-Pierce et al., 2007). Besides  that,  there  are  other  systems  
which  act  as  barriers  to  hamper  the  effective absorption of drug in the body. Protein such as 
P-glycoprotein (or P-gp) is a ATP-binding cassette (ABC) transporter encoded by MDR1 gene 
and is well known for its drug efflux mechanism (Béduneau et al., 2007; Ling, 1997). Because it 
has the capability of removing various toxic substances from cells over-expressing P-gp in such 
organs as liver, kidney, and small intestine, cellular multi-drug resistance (MDR) is developed 
(Thiebaut et al., 1987). In addition to CYP, it is the presence of P-gp in the lower gastro-
intestinal (GI) tract and other multidrug resistance proteins (MRP) , such as MRP 1-5 and breast 
cancer resistance  protein  (BCRP),  that  usually  cause  the  low  oral  bioavailability  of  most 
antineoplastic drugs (Malingré et al., 2001; Schinkel and Jonker, 2003; Varma et al., 2003; 
Varma and Panchagnula, 2005a). Moreover, it has been reported that the synergistic effect 
between P-gp and CYP3A4 could further speed up the first-pass elimination of drugs in intestinal 
enterocytes (Schuetz et al., 1996; Van Asperen et al., 1997; Varma et al., 2004). Therefore, oral 
chemotherapy at home is still not feasible until a very novel, stable and sustained drug 
formulation emerges. Also, P-gp is greatly over-expressed in capillary endothelium of blood 
vessels lining the central nervous system (CNS), which together make up the blood-brain barrier 
(BBB), leading to the failure of chemotherapy to brain cancer due to restricted permeability of 
drugs to tumor sites (Béduneau et al., 2007; Pardridge, 2007). Another reason causing the 
clearance of drugs once they are present in physiological system is the high probability of 
binding to endogenous proteins in the circulatory system. The high-binding affinity of most 
commercial formulations to plasma proteins reduces the amount of free drug required for the 
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treatment at the targeted sites (Rawat et al., 2006). In fact, this protein-binding process, 
especially for hydrophobic drugs, is spontaneous and is part of the opsonization process. In this 
case, the exogenous drugs will be considered as a foreign material (antigen), which promotes the 
binding of opsonins (immunoglobulins, laminin and C-reactive proteins, for example) and will 
eventually be recognized and taken up by phagocytes. This mononuclear phagocyte system   
(MPS),   which   involves macrophages (located in tissues and organs such as liver, spleen, lung 
and lymph nodes) and monocytes (found in blood stream), is also classified as the reticulo-
endothelial system (RES) of the immune mechanism (Hume, 2006; Müller et al., 1997; Owen 
and Peppas, 2006). As a result, sustainability of the drugs is affected. For a drug formulation to 
be effective, solubility, stability and permeability of drugs are the three basic criteria that must be 
fulfilled in order to achieve successful chemotherapy. Unfortunately, sudden exposure of the 
body to certain level of drug dosage for certain time interval is usually an effective way in 
classical chemotherapy for cancer treatment. However, we must also consider the severe side 
effects  due  to the abrupt increase in concentration of cytotoxic drugs in the blood plasma 
because most commercial drugs not only  kill  cancer  cells,  but  also  the  healthy  cells.  Low 
amount of cisplatin, a chemotherapeutic agent that cross-links DNA to retard its replication in 
tumor, can cause serious systemic toxicity to patients if the dosage administered is not properly 
monitored (Sumer and Gao, 2008). Hence, the drugs must not only reach the desired site of 
action and remain accumulated at the site for sufficient period of time, the desired rate of drugs 
being exposed to the patients at certain time must be considered. In fact, controlled release and 
specificity of drugs has become the major factors in designing novel formulations for cancer 
therapy using state-of-the-art bio- and nano-technology. 
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2.4. Anticancer Drugs 
There  are  various  kinds  of  drugs  commercially  available  in  the  market  for  cancer 
chemotherapy.  In generally, all these anticancer drugs are categorized into few groups, 
depending on the way or mechanism by which the drugs act on the cancer cells. Some of them 
include alkylating-like agents, anti-metabolites, anthracyclines and alkaloids. 
Cisplatin, an alkylating-like agent with a structure of cis-Pt(NH3)2Cl2, is used to treat cancers 
such as  small cell lung cancer, colon cancer, ovarian cancer and sarcomas. It contains platinum 
in the molecular structure. The cytotoxic effect of cisplatin is mainly contributed from the 
platinum complexes which can bind and interact with the basic sites of DNA, resulting in DNA 
cross linking (Lippert, 1999).  When the DNA is unable to replicate, apoptosis is induced leading 
to cell death. However, low water solubility, low lipophilicity, serious toxicity and rapid 
inactivation restrict its clinical application (Chupin et al., 2004). Chlorambucil, another 
alkylating-like agent which can be taken orally, is often used for treatment of chronic 
lymphocytic leukemia. Examples  of  anthracyclines  are  daunorubicin  and  doxorubicin  which  
have  been  the effective chemotherapeutic agents for breast cancer, leukemic cells, myeloma 
cells and so on. It is naturally produced by Streptomyces strain of bacteria (Lomovskaya et al., 
1999). This type of drug is believed to intercalate into DNA, thus preventing the growth of 
cancer cells due to the inhibition of enzymes helicase and topoisomerase II which are essential in 
DNA transcription and cell mitosis (Fornari et al., 1994). Another mechanism of action is the 
generation of oxygen free radicals that damage the cell membrane.  The main side effects occur 
especially to the heart include congestive heart failure and arrhythmias.  
Alkaloid is a general group of natural compounds which contain basic nitrogen atoms in the 
molecular structure. Two sub-groups of alkaloids that have the antitumor capability are vinca 
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alkaloids and taxanes. The mechanism of action of these drugs is to interfere with the 
microtubule function in a cell cycle (Cutts, 1961; Kruczynski et al., 1998). While vinca alkaloids 
such as vindesine and vinorelbine can inhibit the assembly of microtubule by reducing the rate of 
tubulin addition, taxanes have the opposite effect, inhibiting the disassembly of microtubules 
during mitosis. 
2.4.1. Taxanes 
The taxanes have emerged as a potent class of chemotherapeutic agents in the treatment of 
various malignancies over the past two decades. Taxanes include paclitaxel and docetaxel, both 
of which are known to have antineoplastic activity against a wide variety of cancer cells. Both 
compounds were approved by the U.S. Food and Drug Administration (FDA) for the treatment 
of several carcinomas including breast, advanced ovarian, non small cell lung, head and neck, 
colon, and AIDS-related Kaposi′s sarcoma. The taxanes are a unique class of hydrophobic anti-
neoplastic agents and exhibit their action against tumor cells by altering the microtubule 
dynamics, which causes cell cycle arrest during mitosis (Schiff et al., 1979).       
Paclitaxel was first discovered in the early 1960s as a part of National Cancer Institute screening 
study to identify natural compounds with anti-cancer properties. Paclitaxel was isolated as a 
crude extract from the bark of the North American pacific yew tree, Taxus brevifolia, and was 
found to possess excellent cytotoxic effects in the preclinical studies against many tumors (Wani 
et al., 1971). Because of the scarcity of the drug, the difficulties in its isolation, extraction and 
formulation, a second taxane drug, Docetaxel was extracted in 1986 from the needles of the 
European Yew Taxus baccata. It is more readily available because of the regenerating capacity 




Docetaxel differs from paclitaxel in the 10-position on the baccatin ring and in the 3'-position of 
the lateral chain, and has a chemical formula of C43H53NO14 and a molecular weight of 807.9 
(Figure 2.1). It is trademarked as Taxotere® (807g/mol) by Rhone Poulenc Rorer, is a complex 
diterpenoid which has a rigid taxane ring and a flexible side chain. It  is  insoluble  in  water,  but  
soluble in 0.1 N hydrochloric  acid,  chloroform, dimethyl formamide,  95%-96%  v/v ethanol,  
0.1 N sodium hydroxide and methanol. The formulation used in the most recent clinical studies 







Figure 2.1: Chemical structure of Docetaxel 
Microtubules are among the most strategic subcellular targets of anticancer agents. Like DNA, 
microtubules are ubiquitous to all eukaryotic cells.  They  are  composed  of  tubulin dimers 
consisting of an α and a β-subunit protein that polymerize and, with numerous microtubule- 
associated proteins (MAPs), decorate the exterior wall of the hollow micro tubule structure 
(Correia, 1991). There is a continuous dynamic equilibrium between tubulin dimers and 
microtubules, i.e., a continuous balance between polymerization and depolymerization.  In  
addition  to  being  an essential component of the  mitotic spindle, and required for the 
maintenance of cell shape, microtubules  are  involved in  a  wide  variety of  cellular activities  
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such  as  cell  motility  and transport between organelles within the cell (Crossin and Carney, 
1981; Edelman, 1976). Furthermore, they may also have a role in modulating the interactions of 
growth factors with cell-surface receptors and the proliferative transmembrane signals produced 
by these interactions.  Many of the unique pharmacologic interactions  of  drugs  with  
microtubules  are  caused  by  a  dynamic  equilibrium  between microtubules and tubulin dimers 
(Rowinsky et al., 1990). Any disruption of the equilibrium, within the microtubule system, 
would be expected to disrupt the cell division and normal cellular activities in which the 
microtubules are involved. Taxanes bind preferentially and reversibly to the β- subunit of tubulin 
in the microtubules rather than to tubulin dimers. The binding site to tubulin differs from the one 
of vinca-alkaloids and podophyllotoxins. While vincas inhibit  polymerization  and  increase 
microtubule disassembly, the  binding of taxanes enhances polymerization of the tubulin into 
stable  microtubules  and further inhibits  microtubule  depolymerization,  thereby  inducing  the 
formation of stable microtubule bundles.  This disruption of the normal equilibrium ultimately 
leads to cell death. As an inhibitor of microtubule depolymerization, docetaxel is approximately 
twice as potent as paclitaxel.  In addition, docetaxel generates tubulin polymers that differ 
structurally from those generated by paclitaxel and does not alter the number of protofilaments in 
the microtubules, while paclitaxel does. 
One of the limitations with the clinical use of docetaxel is that it shows very low water solubility, 
and the only available formulation for clinical use consists of a solution (40 mg/mL) in a vehicle 
containing a high concentration of Tween 80. Unfortunately, this vehicle has been associated 
with several hypersensitivity reactions such as nephrotoxicity, neurotoxicity, and cardiotoxicity. 
In order to overcome the problems faced by Tween 80-based vehicle and in the attempt to 
increase the drug solubility, alternative dosage forms have been suggested, e.g., liposomal 
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formulations for controlled and targeted delivery of the drug (Fernández-Botello et al., 2008). 
2.4.2. Limitations of Taxane formulations 
2.4.2.1. Toxicity of vehicles 
A  high  incidence  of  acute  hypersensitivity  reactions  characterized  by  respiratory  distress, 
hypotension,   angioedema,  generalized  urticaria  and  rash  were  observed  with  paclitaxel 
administration.  It  is  generally  felt  that  cremophor  EL  contributes  significantly  to  these 
hypersensitivity reactions (Weiss et al., 1990; Wiernik et al., 1987). These reactions increased 
with increasing rate of infusion. Docetaxel has also known to cause infusion related reactions in 
the absence of pre medication (Bernstein, 2000). But  these  reactions  occurred  at  a  decreased 
frequency  when  compared  with  paclitaxel and effectively  managed  by  pre  medication.  
Agents formulated with cremophor EL cause peripheral neurotoxicity. The oral formulation 
never induced these adverse side effects. This shows  that  cremophor  EL  is  not  absorbed  
through  the  gastrointestinal  tract.  Furthermore, cremophor EL plasma concentrations achieved 
after i.v (intravenous) administration have been noted to cause axonal swelling, vesicular 
degeneration and demyelination in rat dorsal root ganglion neurons exposed to the formulation 
vehicle (Windebank et al., 1994).  Recent evidences suggest that ethoxylated derivatives of 
castor oil account for this neuronal damage. Polysorbate 80 is also capable of producing 
vesicular degeneration. Sensory neuropathy has also been associated with docetaxel 
administration but the incidences are much lower when compared with paclitaxel. However 
polysorbate 60 containing epipodophyllotoxin etoposide is not a known neurotoxin, suggesting 
that the mechanism of taxane-induced neuropathy may be multi factorial, atleast in part 
contributed by vehicle formulation (ten  Tije et al., 2003). 
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2.4.2.2. Influence of vehicles of pharmacokinetic on taxanes 
Both  cremophor  EL  and  polysorbate  80  have  demonstrated  to  alter  the  disposition  of 
intravenously  administered  Paclitaxel  and  Docetaxel.  Pharmacokinetic studies conducted in 
mouse models and humans have proved that the non-linear pharmacokinetics of Paclitaxel was 
due to Cremophor EL (Sparreboom et al., 1996; van  Tellingen et al., 1999).  This altered 
pharmacokinetics is a resulted of the micellar entrapment of Paclitaxel by cremophor EL in 
plasma. It has been shown that the percentage of Paclitaxel entrapped in micelles increases 
disproportionately with the administration of higher doses of cremophor EL thereby making it 
less available for the tumor tissue distribution, metabolism and biliary excretion (Sparreboom et 
al., 1999). Diminished clearance and prolonged exposure to high concentrations of 
chemotherapeutic agent place patients at higher risk of systemic toxicities. An additional 
problem linked to the cremophor EL solvent is the leaching of plasticizers from 
polyvinylchloride (PVC) bags and infusion sets used routinely in clinical practice. Consequently 
paclitaxel must be prepared and administered in either glass bottles or non-PVC infusion systems 
with in-line filtration. Polysorbate 80 is thought to be rapidly degraded in plasma and does not 
interfere with  kinetics  of  docetaxel (van  Tellingen et al., 1999),  but  recent  evidence  suggest  
that  this  vehicle  may influence the binding of docetaxel in plasma in concentration-dependent 
manner (Loos et al., 2003). 
2.4.2.3. Impact of vehicles on efficacy of taxane 
Some in vitro models have demonstrated that cremophor EL and polysorbate 8- may enhance 
cytotoxic activity by modulating P-glycoproteins (P-gp) and inhibiting multi drug resistance 
gene expression (Friche et al., 1990; Schuurhuis et al., 1990; Woodcock et al., 1990). However 
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this cytotoxic activity was absent in vivo studies due to low volume of distribution of cremophor 
EL and rapid degradation of polysorbate 80 in plasma. Several reports suggest that these 
formulation vehicles may have anti tumor activity on their own. The cytotoxic activity of 
cremophor EL is thought to result from free radical formation by poly unsaturated fatty acids and 
in polysorbate 80, the cytotoxic activity is linked to the release of oleic acid, a fatty acid known 
to interfere with malignant cell proliferation and inhibition of angiogenesis (Chajes et al., 1995; 
Kimura, 2002; Liebmann et al., 1994). 
2.5. Drug carrier vehicles in chemotherapeutic engineering 
In view of the high rate at which cancer is developed and diagnosed in people around the world   
each   year,   various   kinds   of   alternatives   to   more   effectively   deliver   the 
chemotherapeutic agents have been discovered and developed since the past few decades. 
Together with the problems faced in traditional ways in which cancer patients are treated, this 
regimen has even become more and more popular in recent years. The development of new 
nanoparticulate drug formulations is no longer restricted only to chemistry and pharmacy, but is 
a multi-disciplinary area involving technologies from material science, life science, biology as 
well as chemical and biomedical engineering fields. Some of the most common drug delivery 
nanocarriers that are currently developed or under development are liposomes, micelles, 
polymeric nanoparticles and produrgs. The aims of these delivery systems are to minimize drug 
degradation upon administration, prevent undesirable side-effects, and increase  drug  
bioavailability  and  the  fraction  of  the  drug  accumulated  in  the pathological area. 
2.5.1. Liposomes 
Liposomes are drug delivery vehicles which are composed of amphiphilic phospholipids and 
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cholesterol that self-associate into bilayers encapsulating an aqueous interior. These may be 
formulated into small structures (80-100 nm in size) that encapsulate either hydrophilic drugs in 
the aqueous interior or hydrophobic drugs within the bilayer. Liposome can also be formed by 
using biocompatible and biodegradable synthetic lipids or natural/synthetic lipid blends, 
depending on the characteristics required. Other than the non-toxic  effects  of  phospholipids,  
low  immunogenicity  and  reversal  of  multidrug resistance are other advantages of  using 
liposomes as promising drug delivery devices (Thierry et al., 1992; Torchilin, 2005; Warren et 
al., 1992). Encapsulation of drugs is achieved using a variety of loading methods, most notably 
the pH gradient method used for loading vincristine (Waterhouse and Madden, 2005) or the 
ammonium sulfate method for loading doxorubicin. 
 
Figure 2.2: Basic Structure of a liposome 
Additionally, the liposome surface can be engineered to improve its properties (Allen and Sapra, 
2002; Sapra and Allen, 2003). So far, the most noteworthy surface modification is the 
incorporation of polyethylene glycol (PEG) which serves as a barrier, preventing interactions 
with plasma proteins and thus retarding recognition by the reticuloendothelial system (RES) 
(Gabizon and Shmeeda, 2003) and enhancing the liposome circulation lifetime. More advanced 
types of liposomes are under research to further target the liposomes to tumor site. For  
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instance,  Shi  and  Pardridge  have  chemically  modified PEGylated liposome with mouse 
monoclonal antibody OX-26 to form immunoliposomes for targeted and prolong drug or gene 
delivery for brain disorder such as Parkinson’s disease (Shi and Pardridge, 2000). However, 
despite this versatility, there have been major drawbacks to the use of liposomes for targeted 
drug delivery, most notably, poor control over release of the drug from the liposome (i.e. the 
potential for leakage of the drug into the blood), coupled with low encapsulation efficiency, 
manufacturability at the industrial scale and poor stability during storage (Soppimath and 
Aminabhavi, 2001). 
2.5.2. Micelles 
Similar to liposomes, micelles are usually made up of surfactant molecules comprising two 
regions of chains with different hydrophilicity, namely the head and tail groups. Hence, they are 
also capable of encapsulating hydrophobic as well as hydrophilic drugs, thereby increasing the 
solubility and bioavailability. This is one of the attractive properties of micelles as an alternative 
of pharmaceutical nanocarriers. Depending on the nature of the agents to be delivered, different 
processing strategies can be applied to fabricate micelles.  If  a  very  hydrophobic  drug  such  as  
paclitaxel is considered, the liphophilic regions (tail group) of the surfactant will arrange in such 
a way that the core of the micelles containing the drug is excluded and protected from the 
surrounding aqueous phase by the hydrophilic head group. This arrangement is termed oil-in-
water micelle. In contrast, colloidal structures entrapping water-soluble drugs are referred to as 
water-in-oil micelles (or inverse micelles). In recent years, micelles formed from amphiphilic 
diblock or triblock copolymers have gained popular attention in nanomedicine research.  The 
reason is that physiological- friendly building blocks of copolymers can be chosen to construct 
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micelles which have increased half-life and controlled drug release in the body. On the other 
hand, the size of micelles often ranges from 5 – 100 nm, which is the favorable range for passive 
targeting through  enhanced  permeation  and  retention  (EPR)  effect  of  the  leaky  vascular  
and lymphatic system at tumor sites (Hao et al., 2005; Torchilin, 2006). 
 
Figure 2.3: A simple diagram showing (A) micelles, (B) reverse micelles 
Another advantage of polymeric micelles is the narrow size distribution. This is because the self-
assembled core-shell structure of the micelles mainly relies on the thermodynamic equilibrium 
achievable under the particular reaction condition during fabrication process. As a result, 
micellization are also very sensitive to the critical micelle concentration (CMC) of the polymeric 
molecules constituting the micelles (Jones and Leroux, 1999; Lawrence, 1994; Letchford and 
Burt, 2007).  This is perhaps the major concern when designing the materials to be used to 
develop micelles as drug delivery devices. If the concentration drops below the CMC value, 
micelles will tend to dissociate into free chains due to thermodynamic instability. Therefore, this 
becomes a serious issue when it is administered intravenously for treatment. The sudden dilution 
of micelles by the blood and physiological fluids could potentially cause immediate release of 
the encapsulated drug, which could result in severe toxicity (Lawrence, 1994). It happens 
especially to micelles made of conventional surfactants such as ionic surfactants 
(hexadecyltrimethylammonium bromide, cetyltrimethylammonium bromide (CTAB) and sodium 
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dodecyl sulphate (SDS)) or nonionic surfactants (poloxamers and polysorbates), of which CMC 
values are orders higher compared to those of novel, high molecular weight amphiphilic 
polymeric molecules (Rawat et al., 2006).  One creative solution from Prabaharan et al. is to 
synthesize unimolecular micelles inheriting the characteristic of dendrimers by using hyper 
branched polyester as the core structure to make the micelles relatively more solid (Prabaharan et 
al., 2009). For this reason, multifunctional micellar system has been developed for various 
purposes. Simultaneous drug delivery and diagnostic imaging were made possible from the 
research done by Yang et al (Yang et al., 2008). In their formulation, iron oxide nanoparticles 
and doxorubicin were encapsulated in 75 nm micelles formed by poly(ethylene glycol)/poly(ε- 
caprolactone) (PEG/PCL) diblock copolymer which has  been conjugated to folate for specific 
targeting to cancer cells. Other work such as pH-sensitive poly(ethylene glycol)- poly(aspartate 
hydrazone adriamycin) micelles has also been studied by Bae et al. where the acidic condition of 
intracellular endosomes as well as tumor microenvironment can trigger dissociation and the 
release of adriamycin from polymeric micelles, thus increasing the probability of cytoplasmic 
toxicity to cancerous cells (Bae et al., 2005). 
2.5.3. Polymeric nanoparticles 
Polymeric nanoparticles are solid and spherical structure with size ranging from 10 to  
1000 nm, in which drugs are encapsulated within the polymer matrix (Danhier et al., 2010; 
Muthu and Singh, 2009; Torchilin, 2006). The term nanoparticles can be divided into 
nanospheres and nanocapsules. In nanospheres, the drug is dispersed throughout the particles 
whereas in nanocapsules, the drug is entrapped in a cavity surrounded by a unique polymeric 
membrane (Allémann et al., 1993; Hillaireau and Couvreur, 2009).  Polymeric nanoparticles are 
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generally synthesized from biodegradable polymers - like the poly (lactic acid) (PLA) and poly 
(lactic-co-glycolic acid) (PLGA) polyesters or the poly (alkylcyanoacrylates) (PACA) or natural 
polymers, like albumin. Currently, nanoparticles smaller than 200 nm are extensively 
investigated to achieve efficient passive targeting through EPR effect, avoid complement system 
activation and escape from splenic filtration. Moreover, PEGylation and active targeting with 
antibodies, peptides or cell specific ligands has become essential for efficient drug delivery 
systems (Danhier et al., 2010). PEGylation refers to the conjugation of polyethylene glycol to 
drug delivery systems in order to enhance both the stability and circulation time of drug delivery 
systems (Davis, 2002). The effect of PEGylation can also be achieved in drug delivery systems 
prepared by using diblock or triblock copolymers consisting of hydrophilic PEG segment.  
 
Figure 2.4: A representation of Polymeric nanosphere and nanocapsule (Bei et al., 2010) 
For example, MPEG-PLGA, MPEG-PLA, MPEG-PCL and PLA-TPGS copolymers were 
synthesized and used to fabricate drug nanocarriers to achieve PEGylation effect (Aliabadi et al., 
2005; Dong and Feng, 2004; Suh et al., 1998; Zhang and Feng, 2006). An example of 
nanoparticles approved by US FDA as a nanomedicine is albuminbound paclitaxel (Nab™-
paclitaxel), used for treating metastatic breast cancer. This nanoparticle formulation does not 
involve the use of toxic adjuvant Cremophor EL unlike traditional paclitaxel formulation. Due to 
28 
 
the absence of toxic solvents and the albumin receptor mediated delivery, Nab™-paclitaxel tends 
to provide more advantages over traditional solvent-based paclitaxel such as decreased toxicity 
and increased antitumor activity (Stinchcombe, 2007). 
2.5.4. Prodrugs 
Prodrug is a formulation whereby the chemical agents are manipulated at the molecular level 
with the hope to increase their biological activities. It is a common but essential strategy applied 
in drug modification.  This strategy usually involves direct chemical modification of bioactive 
agents to enhance their solubility, stability and permeability in physiological conditions to 
optimize absorption, distribution, metabolism and excretion (ADME) properties of the original 
drug compounds (Nielsen et al., 1994; Stella et al., 1998; Testa and Caldwell, 1996; Vyas et al., 
1993). To achieve this objective, modification of functional group or conjugation of the drugs to 
polymeric or targeting molecules is often done to convert the drugs to its inactive form. Thus, 
when the modified inactive drugs are administered into the body, they can bypass some of the 
various physiological barriers such as gastro-intestinal (GI) tract or RES. After undergoing the 
metabolic process in vivo, the breakdown of the molecule into the corresponding constituents 
then restores the original bioactive form of the drug. In other words, prodrug exhibits the 
potential to increase the bioavailability of poorly soluble drugs as well as to enhance their 
biological effects in the body by prolonging the duration of action. One  classical  example  of  
functional  group-modified  prodrug  is  the  pharmaceutical compound called levodopa (L-3, 4-
dihydroxy-phenylalanine), used in clinical treatment of Parkinson’s disease which is   
characterized   by  severe   depletion   of neurotransmitter dopamine in brain. Unlike dopamine, 
levodopa is capable of crossing the blood-brain barrier (BBB) through neutral amino acid 
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transporter. After BBB permeation of levodopa, decarboxylase enzymes, mostly found in brain 
tissues, converts levodopa to dopamine, thereby increasing the dopamine concentration in brain.  
 
Figure 2.5: A simple representation of Prodrug concept (Jayant Khandare, 2006) 
In recent years, some polymers serving as a backbone for therapeutic agents as well as targeting  
moieties  to  be  chemically  attached  have  attracted  significant  attention  in biomedical fields. 
For example, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer conjugated with 
anticancer drug daunomycin or doxorubicin and targeting ligands such as monosaccharides and 
antibody demonstrated decreased toxicity to normal tissues and low immunogenicity in vivo 
(Kopecěk, 1990). Meanwhile, polymer-anti cancer drug conjugates such as HPMA/doxorubicin 
and PEG-camptothecin conjugate have also shown promising therapeutic effect and has gone 
further into clinical trial due to its synthetic, non-immunogenic, biocompatible and water-soluble 
properties which could make oral drug delivery feasible (Duncan et al., 2006; Veronese et al., 
2005). Furthermore, Cao et al. showed that doxorubicin   conjugated to d-α-tocopheryl 
polyethylene glycol 1000 succinate (or Vitamin E TPGS) exhibited significant cellular uptake of 
cancer cells in vitro, more than 3-fold longer circulation half-life in rats as well as much lower 
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drug accumulation in heart and intestine compared to the free drug (Cao and Feng, 2008).  This 
implies that polymer-drug conjugate could greatly change the pharmacokinetic, 
pharmacodynamic and improve therapeutic index of the pristine drug (Maeda et al., 1992). 
However, some limitations of this formulation include the cytotoxicity of the polymer used, the 
limited site of polymer for drug conjugation and the possibility of denaturing the bioactivity of 
the drug molecule when certain functional groups are permanently modified during chemical 
reaction. Lack of activating enzymes in certain human tumors may also be another drawback for 
prodrug therapy (Connors and Knox, 1995). 
2.6. Liposomes: Preparation methods and their types 
An important parameter to consider when addressing the formation process of liposomes is the 
rigidity of the bilayer. As previously mentioned liposomes are composed of phospholipids and 
the thermal characteristic of these phospholipids dictates the fluidity of the bilayer. They undergo 
a phase transition at temperatures lower than the melting point (Tm) known as the crystalline 
transition temperature (Tc). At this temperature the lipidic bilayer loses much of its ordered 
packing and can be in a liquid-crystalline (‘fluid’) state or in a gel state. The presence of 
branched chains and unsaturated acyl chains in phospholipids lowers the Tc. Liposomes made up 
of pure phospholipids will not form at temperatures below the Tc of phospholipids and to reduce 
this temperature dependency, cholesterol is being added in the formation of liposomes. The 
preparation method should be carried out well above the Tc of the vesicles so as to ensure that all 
the phospholipids are dissolved in the suspension medium homogeneously and have sufficient 
flexibility to align themselves in the structure of lipid vesicles (Mozafari, 2010). Therefore the 
transition temperature is considered as an important factor in the preparation of liposomes. The 
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Tc of a bilayer depends on: 
1. Acyl chain length. 
2. Degree of saturation. 
3. Polar head group. 
4. Nature and ionic strength of the suspension medium 
Based on their preparation methods, the liposomes are classified into the following three 
different types. 
2.6.1. Multilamellar Liposomes (MLV) 
2.6.1.1. Lipid Hydration Method 
This is the most widely used method for the preparation of MLV. The method involves drying a 
solution of lipids so that a thin film is formed at the bottom of a round bottomed flask and then 
hydrating the film by adding aqueous buffer and vortexing the dispersion for some time. The 
hydration step is done at a temperature above the gel-liquid crystalline transition temperature Tc 
of the lipid or above the Tc of the highest melting component in the lipid mixture. The 
compounds to be encapsulated are added either to aqueous buffer or to organic solvent 
containing lipids depending upon their solubilities. Multilamellar vesicles can be easily prepared 
by this method and a variety of substances can be encapsulated in these liposomes. The 
drawbacks of the method are low internal volume, low encapsulation efficiency and the size 




Figure 2.6: A schematic presentation for the steps involved in lipid hydration method 5 
 Many different variations have been developed for the user’s suitability which varies with 
respect to the organic solvent used, possible addition of inert glass or Teflon beads, way of 
drying lipid film and parameters of agitation such as time, intensity, mode and temperature. On 
the other hand, MLVs with high encapsulation efficiency can be prepared by hydrating the lipids  
in the presence of an immiscible organic solvent (petroleum ether, diethyl ether). The contents 
are emulsified by vigorous vortexing or sonication. The organic solvent is removed by passing a 
stream of nitrogen gas over the mixture. MLVs are formed immediately in the aqueous phase 
after the removal of organic solvent (Gruner et al., 1985; Papahadjopoulos and Watkins, 1967). 
The main drawback of this method is the exposure of the materials to be encapsulated to organic 






2.6.1.2. Solvent Spherule Evaporation Method 
A method for the preparation of MLVs of homogeneous size distribution was proposed by Kim 
et al. (Kim et al., 1985). The process involved dispersing in aqueous solution the small spherules 
of volatile hydrophobic solvent in which lipids had been dissolved. MLVs were formed when 
controlled evaporation of organic solvent occurred in a water bath.  
2.6.2. Small Unilamellar Liposomes (SUV) 
2.6.2.1. Sonication Method 
Here MLVs are sonicated either with a bath type sonicator or a probe sonicator under an inert 
atmosphere. The former method has the advantage that there is no direct contact of liposomes 
with the source of ultrasound waves but the energy density of typical bath sonicators are in 
general too low to produce homogeneous and small unilamellar vesicles. Direct tip sonication is 
still probably the most widely used method for the preparation of SUV’s, at least in small scales. 
 
Figure 2.7: A schematic presentation of tip and bath sonicator (Lasic, 1993)  
Apart from these, the main drawbacks of this method are very low internal volume/encapsulation 
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efficiency, possibly degradation of phospholipids and compounds to be encapsulated, exclusion 
of large molecules, metal contamination from probe tip and presence of MLV alongwith SUV. 
Oezden and Hasirci (Oezden and Hasirci, 1991) have prepared a polymer coated liposomes by 
this method. 
2.6.2.2. French Pressure Cell Method 
The method involves the extrusion of MLV at 20,000 psi at 4°C through a small orifice. The 
method has several advantages over sonication method. The method is simple, rapid and 
reproducible and involves gentle handling of unstable materials (Hamilton and Guo, 1984). The 
resulting liposomes are somewhat larger than sonicated SUVs. Normally the working volumes 
are upto 50 ml and after several extrusions rather small and unilamellar vesicles are produced. 
The drawbacks of this method are low maximal concentrations and not too well defined size 
distribution of vesicles produced. It is not easy to operate at higher temperature in this method 
and is basically used for lipids with Tc < 20 ̊ C.  
2.6.2.3. Support based hydration method 
This method was given by Lasic et al. (Lasic et al., 1987) and used for the preparation of SUV. 
They deposited egg phosphatidylcholine mixed with 1.5 %w/v of cetyl tetramethylammonium 
bromide (a detergent) in CHCI3/CH3OH on various supports for example silica gel powder, 
zeolite X, zeolite ZSM5. After the removal of organic phase, the system was resuspended by 
shaking or stirring in distilled water or 5 mM NaCl. There was some loss of phospholipid (about 
10-20%) due to adsorption on the supports. The loss was 70% and 95% in the case of silica gel 
and zeolite ZSM5 respectively. An homogenous population of vesicle with average diameter of 
21.5 nm was obtained when zeolite X (particle size of 0.4 mm) was used as a support. 
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2.6.3. Large Unilamellar Liposomes (LUV) 
They have high internal volume/encapsulation efficiency and are now days being used for the 
encapsulation of drugs and macromolecules. 
2.6.3.1. Solvent Injection Methods 
(a) Ethanol Injection Method 
A lipid solution of ethanol is rapidly injected to a vast excess of buffer or aqueous solution. The 
LUVs are immediately formed. The method is rather simple to scale up and has also found 
applications in large scale production methods. The drawbacks of the method are that the 
population is heterogeneous (30-110 nm), liposomes are very dilute, it is difficult to remove all 
ethanol because it forms azeotrope with water and the possibility of various biologically active 
macromolecules to inactivation in the presence of even low amounts of ethanol (Batzri and Korn, 
1973). 
 
Figure 2.8: A schematic presentation of ethanol injection method (Lasic, 1993) 
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(b) Ether Infusion Method 
This method is an analogue to the ethanol injection method with the exception of the fact that the 
solvent is not miscible with water. A solution of lipids dissolved in diethyl ether or 
ether/methanol mixture is slowly injected to an aqueous solution of the material to be 
encapsulated at 55-65°C or under reduced pressure. The subsequent removal of ether under 
vacuum leads to the formation of liposomes. The main drawbacks of the method are that the 
population is heterogeneous (70-190 nm) and the exposure of compounds to be encapsulated to 
organic solvents or high temperature (Deamer and Bangham, 1976; Schieren et al., 1987). 
2.6.3.2. Detergent Removal Methods 
This method is considered a very mild treatment and even many sensitive proteins, whose 
activity cannot survive other physical or chemical treatments, can be incorporated into liposomes 
unchanged if the proper non denaturating detergent can be used. The detergents at their critical 
micelles concentrations have been used to solubilize lipids. As the detergent is removed the 
micelles become progressively richer in phospholipid and finally combine to form LUVs. The 
detergents were removed by dialysis (Alpes et al., 1986; Kagawa and Racker, 1971; Milsmann et 
al., 1987). The advantages of detergent dialysis method are excellent reproducibility and 
production of liposome populations which are homogenous in size. The main drawback of the 
method is the retention of traces of detergent(s) within the liposomes. A commercial device 
called LIPOPREP (Diachema AG, Switzerland) which is a version of dialysis system is available 
for the removal of detergents. Other techniques have been used for the removal of detergents: (a) 
by using Gel Chromatography involving a column of Sephadex G-25, (b) by adsorption or 
binding of Triton X-100 (a detergent) to Bio-Beads SM-2. (c) by binding of octyl glucoside (a 
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detergent) to Amberlite XAD-2 beads. 
2.6.3.3. Reverse Phase Evaporation Method 
Reverse phase evaporation method, besides sonication and detergent removal techniques, is the 
most widely used in liposomes research. In this method, water in oil emulsion is formed by brief 
sonication of a two phase system containing phospholipids in organic solvent (diethylether or 
isopropylether or mixture of isopropyl ether and chloroform) and aqueous buffer. The organic 
solvents are removed under reduced pressure, resulting in the formation of a viscous gel. The 
liposomes are formed when residual solvent is removed by continued rotary evaporation under 
reduced pressure. With this method high encapsulation efficiency up to 65% can be obtained in a 
medium of low ionic strength, for example 0.01 M NaCl. The method has been used to 
encapsulate small, large and macromolecules. The main disadvantage of the method is the 
exposure of the materials to be encapsulated to organic solvents and to brief periods of 
sonication. These conditions may possibly result in the denaturation of some proteins or 
breakage of DNA strands (Szoka and Papahadjopoulos, 1978). We get a heterogeneous sized 
dispersion of vesicles by this method. Modified Reverse Phase Evaporation method was 
presented by Handa et al. (Handa et al., 1987) and the main advantage of the method is that the 
liposomes had high encapsulation efficiency (about 80%). The Reverse Phase Evaporation 
method of Szoka and Papahadjopoulos (1978) has also been modified to entrap plasmids without 
damaging DNA strands. 
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2.7. Vitamin E TPGS, an amphiphilic polymer  
2.7.1.   Structure and Properties  
Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate or TPGS) is a water  
soluble derivative of natural vitamin E and prepared by esterification of d-α-tocopheryl acid  
succinate with polyethylene glycol 1000. It is an amphiphilic macromolecule comprising of  
hydrophilic polar head and a lipophilic alkyl tail. Its molecular weight is approximately 1542 Da. 
 
Figure 2.9: Chemical structure of Vitamin E TPGS 6 
The hydrophile/lipophile balance (HLB) of TPGS is ~13. It is basically a waxy solid appearing 
white to light brown in color with a melting point approximately 37-41°C. It is stable in air as 
well. It is used an effective emulsifier as well as a good solubilizer due to its bulky nature and 
larger surface area (Fisher et al., 2002). The chemical structure of TPGS was shown in Figure 
2.9. TPGS has found wide utility in pharmaceutical formulations as follows.  
 Improving drug bioavailability  







 Stabilization of the amorphous drug form  
 Enhances drug permeation by P-glycoprotein efflux inhibition 
 Emulsion vehicle  
 Functional ingredient in self-emulsifying formulations 
 Thermal binder in melt granulation/extrusion processing 
 Reducing drug sensitivity on skin or tissues 
 Carrier for wound care and treatment  
 Water-soluble source of vitamin E  
2.7.2.   Absorption/Bioavailability Enhancer  
TPGS has received increased attention in the literature for its ability to enhance the absorption of 
several drugs that have otherwise poor bioavailability. Sokol et al. in 1991 clinically 
demonstrated that TPGS can enhance absorption of the highly lipophilic drug cyclosporin, which 
is used for immunosuppressive therapy to manage rejection of transplanted organs. This is a 
crucial finding for organ transplant recipients. Due to the impaired absorption of cyclosporine, 
massive doses are required to achieve therapeutic blood plasma concentrations. The study 
showed that TPGS provides a substantial improvement of cyclosporine absorption and a 
significant reduction of the high cost of immunosuppressive therapy. While Sokol originally 
suggested that the increased bioavailability was due to micelle formation enhancing the 
solubility, others have since provided evidence supporting enhanced permeability due to P-
glycoprotein (P-gp) inhibition (Croockewit and Koopmans, 1996; Dintaman and Silverman, 
1999). While many of the examples of TPGS use are poorly water soluble drugs there are also 
40 
 
examples of using TPGS with poorly permeable drugs that are water soluble (Prasad and Puthli, 
2003). Many studies have been conducted to evaluate the mechanism by which TPGS affects 
bioavailability. Its action is attributable to its ability to improve solubility through micelle 
formation and through enhancing permeability across cell membranes by inhibition of multi-drug 
efflux pump P-gp. For oral delivery, TPGS enhances drug efficacy by improving the 
solubilization or emulsification of the drug in the finished dosage form and through formation of 
a self-emulsifying drug delivery system in the stomach which may be due to TPGS, which 
improves the permeability of a drug across cell membranes by inhibiting P-glycoprotein and thus 
enhance absorption of a drug through intestinal wall and into the bloodstream. It can act as a 
reversal agent of P-gp mediated multidrug resistance and inhibit P-gp substrate drugs transport 
(Dintaman and Silverman, 1999). TPGS is more effective P-gp inhibitor than many related 
excipients with surfactant properties such as cremophor EL, Tween 80, Pluronic P85 and PEG 
300. However, it is significantly less potent than other clinically tested pharmacologically active 
compounds such as cyclosporine, tariquidar and zosuquidar (Dantzig and Law, 2001; Mistry and 
Stewart, 2001).  
2.7.3.   Emulsifier and Solubilizer  
It is estimated that over 40% of new drug entities are poorly water soluble. Some drug delivery  
systems that can utilize the solubilizing ability of TPGS are solid dispersions, self-emulsifying  
drug delivery systems, self-microemulsifying drug delivery systems, spray drying and others.  
Much work has been done to investigate the effect of TPGS on the aqueous solubility of poorly  
water soluble drugs. It was shown that TPGS can enhance the solubility and bioavailability of  
poorly absorbed drugs by acting as a carrier in drug delivery systems, thus providing an effective 
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way to improve the therapeutic efficiency and reduce the side effects of the anticancer drugs 
(Fisher et al., 2002; Youk and Lee, 2005). One of the early discoveries on the solubilizing 
potential of TPGS is attributable to the work of Ismailos et al. who followed up on the discovery 
that TPGS can be co-administered with cyclosporine - A resulting in dramatic decrease in the 
dosage required of this costly drug (Ismailos, 1994). Also, it was found that TPGS improves the 
solubility of the poorly water soluble drug amprenavir (Yu and Bridgers, 1999). Below the 
critical micelle concentration, there is no increase in solution. A more recent application involves 
taxoids which, while important for their chemotherapeutic action, are poorly water soluble and 
difficult to administer in oral formulation. TPGS is one of the best excipients in which taxoids 
are soluble. It shows excellent solubilization properties for oral formulation containing paclitaxel 
and TPGS (Varma and Panchagnula, 2005a).  
2.7.4. Agent for Controlled Delivery Applications  
TPGS can be a good emulsifier or surfactant in fabricating nano/microparticles. TPGS 
emulsified PLGA nanoparticles fabricated by a modified solvent extraction/evaporation method 
have narrow polydispersity range from 0.005-0.045 and size around 300-800 nm. TPGS can also 
achieve emulsification efficiency as the amount of TPGS needed in the fabrication process was 
only 0.015% (w/w), which was far less than 1% for PVA needed in similar process (Mu and 
Feng, 2002; Mu and Feng, 2003a). Mu and Feng also found that TPGS could be a good 
component of the polymeric matrix material in fabrication of PLGA nanoparticles.  Feng et al 
found that nanoparticles coated with TPGS eliminated the side effects caused by human 
intestinal epithelia cells and cancer cell mortality (Feng and Mu, 2004). The polymeric 
nanoparticles, in which active agent is dissolved, entrapped, encapsulated, adsorbed, attached or 
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chemically coupled, are an exciting new area of research. Here the co-polymerization of TPGS 
with a polymer such as PLZ, PCL or PLGA can improve the emulsification efficiency, drug 
encapsulation efficiency and enhance the cellular uptake of the nanoparticles, thereby increasing 
the therapeutic effect. These have been demonstrated on microencapsulated paclitaxel (Zhang 
and Feng, 2006). TPGS is also said to be a more effective and safer emulsifier than PVA with 
easier usage in fabrication and characterization of polymeric nanospheres for drug delivery (Mu 
and Feng, 2002). 
2.7.5. TPGS – an anti-neoplastic agent 
TPGS is PEG 1000- conjugates to derivative of α-tocopheryl succinate (TOS) while TOS is a  
succinyl derivative of vitamin E and has been found to have anticancer properties against  
leukemia, melanomas, breast, colorectal, malignant brain, lung and prostate cancers (Neuzil and 
Weber, 2001; Yu and Liao, 2001). TOS differs from other vitamin E derivatives in that TOS 
itself does not act as an antioxidant (Neuzil, 2002). In xenograft experiments, TOS suppressed 
tumor growth, both alone and in combination with other anticancer agents (Barnett and Fokum, 
2002; Weber and Lu, 2002). The anticancer activity of TOS is mediated by its unique apoptosis-
inducing properties which appear to be mediated through diverse mechanisms involving the 
generation of reactive oxygen species (ROS) (Wang and Witting, 2005). These ROS can damage 
DNA, proteins and fatty acids in cells resulting in apoptotic cell death depending on the strength 
and duration of ROS generation. It has poor water solubility but its conjugation to PEG makes it 




2.8.1. Structure and functional aspects of Herceptin 
Herceptin® (Trastuzumab, HER) is a humanized, monoclonal antibody targeted against the 
extracellular domain of transmembrane receptor protein (c-erB2/HER2/neu), which is 
overexpressed in certain types of breast cancer (Nahta and Esteva, 2006; Pohlmann et al., 2009). 
It has been approved as therapeutic agent of breast cancer by US FDA. The model structure of 
herceptin is given in Figure 2.10.  
 
Figure 2.10: Structure of Herceptin 
It consists of two antigen-specific sites that bind to the juxtamembrane portion of the 
extracellular domain of the HER2 receptor and that prevent the activation of its intracellular 
receptor tyrosine kinase. The remainder of the antibody is a human IgG with a conserved Fc 
portion (Cho et al., 2003). Herceptin is presented as a white to pale yellow lyophilized powder 
and this concentrate has been diluted in solution for infusion. It is being indicated for the 
treatment of patients with metastatic breast cancer where HER2 is over expressed.  
2.8.2. Structure and functional aspects of HER2 receptors 
HER2 is a 185-kDa transmembrane oncoprotein encoded by the HER2/neu gene and over-
expressed in approximately 20 to 25% of invasive breast cancers (Pohlmann et al., 2009). It is a 
member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor 
tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and 
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HER4 (ERBB4). These receptors comprises of an extracellular region of about 630 amino acids 
that contains four domains (I/L1, II/CR1, III/L2 and IV/CR2) arranged as a tandem repeat of a 
two-domain unit, a single membrane-spanning region and a cytoplasmic tyrosine kinase (Hudis, 
2007). Binding of ligand to the extracellular region induces receptor dimerization and activation 
of the cytoplasmic kinase (receptor tyrosine kinase, RTK), which in turn leads to the 
autophosphorylation and initiation of downstream signaling events. Among all the ErbB receptor 
family, HER2 has the unusual ability to transform into oncogenic in a ligand – independent 
manner when overexpressed. The downstream signaling events of this receptor family are shown 
in Figure 2.11 (Arteaga et al., 2011).  
 
Figure 2.11: Types and functions of HER2 receptors (Arteaga et al., 2011) 
The signaling cascade following the phosphorylation of RTKs leads to the activation of the 
PI3K/Akt and the Ras/Raf/MEK/MAP kinase pathways thereby regulating the cell growth, 
survival and differentiation (Valabrega et al., 2007). Thus at any instance overexpression of 
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HER2 receptor induces oncogenesis in patients characterized by HER2 – positive breast cancer. 
2.8.3. Mechanism of action of Herceptin on HER2 
Various in vitro and in vivo experimental models have been carried out and observed for the 
possible effects of herceptin on the regression and inhibition of HER2 overexpressing tumors. 
The following are some of the proposed mechanism of action of herceptin and an overall scheme 
was shown in Figure 2.12 (Nahta and Esteva, 2006).  
 
Figure 2.12: Mechanism of action of Herceptin (Nahta and Esteva, 2006) 
As already mentioned, HER2 activates multiple signaling pathways such as PI3 kinase and MAP 
kinase cascades leading to cell growth and proliferation. Binding of herceptin on HER2 blocks 
the ligand binding and disrupts the receptor activation by either homodimerization or 
heterodimerization. This inhibits further downstream signaling pathways and eventually 
promotes cell cycle arrest and apoptosis (programmed cell death). The G1 phase of cell cycle is 
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being arrested by reducing the expression of proteins which maintains the sequestration of 
cyclin-dependent kinase inhibitor p27. This paved the way for p27 to bind and inhibit cyclin 
E/cdk2 complexes, blocking the cell cycle (Nahta and Esteva, 2006). It was reported that 
treatment with herceptin reduced the angiogenesis caused by the overexpression of HER2 in 
human tumor cells. In vitro results showed that there has been reduced endothelial cell migration. 
This phenomenon was attributed to the increased expression of anti-angiogenic factors and 
reduced expression of pro-angiogenic factors. 
 In vivo breast cancer models and clinical trials have demonstrated that herceptin is not 
only cytostatic but also cytotoxic. This ability was related in part to the activation of antibody – 
dependent cellular cytotoxicity (ADCC). ADCC is mainly due to the activation of natural killer 
cells (NK) of the immune system, expressing the Fc gamma receptor, which can be bound by the 
Fc domain of herceptin (Arteaga et al., 2011; Nahta et al., 2006; Valabrega et al., 2007). It was 
reported that herceptin has the ability to inhibit DNA repair and promotes DNA strand breaks 
specifically in HER2 overexpressing BT474 and SKBR3 cells. Also it has been shown that 
herceptin is synergistic with various chemotherapeutic drugs, especially with the DNA damaging 










CHAPTER 3: PREPARATION AND CHARACTERIZATION OF VITAMIN E TPGS 
COATED AND HERCEPTIN CONJUGATED LIPOSOMES 
3.1. Introduction 
Liposomes are biocompatible and can be used as model cell membranes for elucidating the 
interactions and functions of proteins with cell membrane. Dipalmitoylphosphatidylcholine 
(DPPC), a phospholipid and one of the major constituent for biological cell membranes was used 
to prepare liposomes. Vitamin E TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate), 
an amphillic copolymer was incorporated into the lipid bilayer for three main reasons such as    
1) to improve the mechanical stability of the bilayer, 2) to enhance the bioavailability and 
circulation time, 3) as a linker for conjugating herceptin on the surface of liposomes. In this 
chapter, the focus will be on the preparation methods and characterization of TPGS coated 
liposomes and herceptin conjugated liposomes. For the latter case, TPGS was reacted with 
succinic anhydride by the ring opening polymerization mechanism in the presence of DMAP to 
form succinoylated TPGS, containing carboxyl end groups. All the liposomal formulations used 
in this study were prepared using solvent injection method. These liposomes are then 
characterized for their particle size and size distribution (photon correlation spectroscopy, PCS), 
zeta potential (Zetasizer), surface morphology (transmission electron microscopy, TEM and 
atomic force microscopy, AFM), surface properties (x-ray photoelectron spectroscopy, XPS), 
encapsulation efficiency (EE) and in vitro drug release profile. Further, the conjugation of 
herceptin and the molecular arrangement of succinoylated TPGS inside the lipid bilayer was 
studied by Fourier transform infrared spectroscopy (FTIR) and differential scanning Calorimetry 




Docetaxel of purity 99.56% was purchased from Jinhe Bio-Technology Co. Ltd (Shanghai, 
China). 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) was a generous gift from 
Lipoid GmbH (Ludwigshafen, Germany). D-α-tocopheryl polyethylene glycol 1000 succinate 
(TPGS) C33O5H54 (CH2CH2O)23 was from Eastman chemical company (Kingsport, TN, USA). 
Herceptin (20 mg in 0.95 ml) was offered by Singapore General Hospital, Singapore. 
Cholesterol, acetone, methanol, ethanol, phosphate buffer saline (PBS), Dichloromethane 
(DCM), Dimethylaminopyridine (DMAP), SA, Coumarin-6, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), N-hydroxysuccinimide (NHS) were purchased from Sigma–Aldrich (St. 
Louis, MO, USA). Tween-80 was from ICN Biomedicals, Inc. (OH, USA). Clinical formulation 
Taxotere® was supplied by Aventis Pharmaceuticals, USA. All solvents such as acetonitrile, 
methanol and ethanol were of high performance liquid chromatography (HPLC) grade. All 
chemicals were used without further purification. Millipore water was prepared by a Milli-Q Plus 
System (Millipore Corporation, Bredford, USA). 
3.3. Methods 
3.3.1. Preparation of succinoylated TPGS 
Succinoylated TPGS was synthesized by the ring-opening polymerization mechanism in the 
presence of DMAP as described in our earlier work (Anbharasi et al., 2010). In brief, TPGS 
(0.77 g), SA (0.10 g) and DMAP (0.12 g) were mixed and allowed to react at 100 ̊ C under 
nitrogen atmosphere for 24 h. The mixture was cooled to room temperature and taken up in 5.0 
ml cold DCM. It is then filtered to remove excessive SA and precipitated in 100 ml diethyl ether 
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at ˗10 ̊ C overnight. The white precipitate was filtered and dried in vacuum to obtain 
succinoylated TPGS (TPGS-COOH). 
3.3.2. Preparation of docetaxel or coumarin-6 loaded liposomes 
Conventional (non-coated), TPGS and TPGS-COOH coated liposomes were prepared according 
to the solvent injection method (Muthu et al., 2011). In brief, docetaxel/coumarin-6, DPPC, 
cholesterol and TPGS or TPGS-COOH (added only in the preparation of coated liposomes) were 
dissolved in 0.3 ml of ethanol at 60° C, according to the formulae (Table 3.1).  
Table 3.1: Formulation of liposomes 
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  8:7.7:1 
        - 
        - 
         0.3 




COOH   8:7.7:1         -           0.3 
DTX: Docetaxel loaded 
CM6: Coumarin-6 loaded 
TP: Liposomes prepared with TPGS 
TP-COOH: Liposomes prepared with TPGS-COOH 




The mixtures were injected into 2.7 ml of 1mM phosphate buffered saline (PBS), pH 7.4 
isothermally at 60° C. The suspensions formed were kept at 60° C under stirring for 60 min to 
form multilamellar vesicles (MLV).  The small unilamellar vesicles (SUV) were prepared from 
the MLV suspensions by ultrasonication (Vibra Cell™, 130w, 20 kHz) for 5 min followed by 
filtration through 0.22 µm filter while keeping the lipids above the phase transition temperature 
(Tm). Finally, liposomes (SUV) were centrifuged at 11,000 rpm for 15 min to remove the excess 
non-incorporated drug and stored at 4° C. Liposomes formulae were established to get higher 
drug encapsulation, controlled drug release and stability (Figure 3.1C and 3.1D). 
3.3.3. Preparation of Herceptin conjugated Liposomes 
Herceptin was diluted in PBS (pH 7.9) to acquire 5 mg/ml concentration as stock solution. 
Antibody conjugated liposomes were prepared according to a procedure similar to that described 
by Jun Liu et al (Liu et al., 2007). Briefly TPGS-COOH coated liposomes (0.3ml, 2.5 mg/ml 
with respect to TPGS-COOH) was diluted in PBS (pH 5.5) and incubated with 200 μl of 100 
mM EDC and 200 μl of 25 mM of NHS for 30 min under room temperature with gentle stirring. 
The activated particles were incubated with 0.5 ml of Herceptin solution for another 30 min at 
room temperature. The resulting antibody-liposome conjugates were dialyzed in saturated 
solution of docetaxel/coumarin-6 to make non-sink condition of docetaxel/coumarin-6 while 
removing the by-products. The size of the dialysis membrane used was 1000 Da. 
3.3.4. Characterization of liposome formulations 
3.3.4.1. Particle size, polydispersity, zeta potential 
Size, polydispersity and zeta potential of the liposomes were measured by photon correlation 
spectroscopy (PCS) using Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK). The 
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liposome samples were analyzed after 50 times dilution with deionized water to a count rate of 
100-300 kcps.  
 
 
Figure 3.1: Schematic diagram of (A) Placebo liposome (B) Docetaxel loaded liposome (C) TPGS-COOH 
coated liposome (D) Herceptin conjugated liposome 
3.3.4.2. Surface morphology 
The surface properties of TPGS-COOH coated liposomes were visualized by an atomic force 
microscope (AFM) (Digital 3000 Nanoscope, Santa Barbara, California, USA) under normal 
atmospheric conditions. Explorer atomic force microscope was set in tapping mode, using high 
resonant frequency (F0 = 346 kHz) pyramidal cantilevers with silicon probes having force 
constants of 41 N/m. Scan speed was set at 1 Hz. The sample was diluted 50 times with distilled 
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water and then dropped onto glass slides, followed by vacuum drying during 24 h at 25 °C. The 
measurements were obtained using AFM image analysis software (Nanoscope 5.30). 
Surface morphology was also studied by a field emission transmission electron microscopy 
(FETEM) system (JEM 2010F, JOEL, Japan). Samples of conventional non-coated and TPGS-
COOH coated liposomes were prepared by placing one drop on a copper grid and dried under 
vacuum pressure. The dried liposomes being stained with 1% phosphotungstic acid for 30 s were 
finally examined. 
3.3.4.3. Surface chemistry 
X-ray photoelectron spectroscopy (Kratos Ultra DLD, Shimadzu, Japan) was used to investigate 
the surface chemistry of the targeted and non-targeted liposomes. The fixed transmission mode 
was utilized with a passing energy of 80eV and the binding energy spectrum was analyzed from 
0 to 1100 eV. 
3.3.4.4. FTIR spectroscopy 
The Fourier transform infrared (FTIR) spectra for TPGS-COOH coated liposomes and herceptin 
conjugated liposomes were obtained from the FTIR Spectrophotometer (FTIR 8400S, Shimadzu) 
for characterizing the surface modification of herceptin on the liposomes. The scanning range 
was 400-4000 cm-1 and the resolution used was 2 cm-1. 
3.3.4.5. Differential Scanning Calorimetry 
DSC experiments were performed using a Mettler Toledo DSC822 differential scanning 
calorimeter. Hermetically aluminum sealed pan (40 μl) was filled with approximately 10 mg of 
sample solution, while an empty pan was used as the reference. The data were collected from -10 
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to 60 °C at a scan rate of 2.5 °C/min. The molecular arrangement of TPGS-COOH and docetaxel 
within the bilayer was assessed in comparison with the conventional liposomes prepared without 
TPGS-COOH and docetaxel. 
3.3.4.6. Drug/dye encapsulation efficiency 
The docetaxel encapsulated in the liposomes was measured by HPLC (Agilent LC1100, Agilent, 
Tokyo, Japan). A reverse-phase HPLC column (Agilent Eclipse XDB-C18, 4.6 × 250 mm, 5 μm) 
was used. Briefly, 20 μl of drug loaded liposomes were mixed with 80 μl of methanol for 
liposomes disruption and dissolved in mobile phase consisting of acetonitrile and deionized 
water (50:50, v/v) to 1 ml. The solution was filtered through 0.45 μm syringe filter before 
transferred into HPLC vial. The flow rate of mobile phase was set at 1.0 ml/min. The column 
effluent was detected with a UV/VIS detector at 230 nm. The calibration curve was linear in the 
range of 50–50,000 ng/ml with a correlation coefficient of R2 = 0.999. The drug encapsulation 
efficiency was defined as the ratio between the amount of docetaxel encapsulated in the 
liposomes and that added in the liposomes preparation process. 
For fluorescent liposomes, the coumarin-6 encapsulation efficiency was determined by the same 
dilution process as described for the drug-loaded liposomes. The fluorescence was measured by 
HPLC with a flow rate of 1.3 ml/min mobile phase consisting of acetonitrile/deionized water 
(60:40 v/v). The excitation and emission wavelength were set at 462 nm and 502 nm, 
respectively, using a fluorescence detector module. 
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3.3.4.7. Invitro drug release 
The dialysis bag diffusion technique was used to study the in vitro drug release from the 
docetaxel loaded liposomes (Muthu et al., 2009). The drug loaded liposomes of a volume 
equivalent to 25 μg of docetaxel were placed in the dialysis bag (cellulose membrane, molecular 
weight cut off 1,000 Da), hermetically sealed and immersed into 20 ml of phosphate buffered 
saline (pH 7.4) containing 0.1% w/v Tween 80. The entire system was kept at 37±0.5 °C with 
continuous shaking at 100 rpm/min. Samples were withdrawn from the receptor compartment at 
predetermined time intervals and replaced by fresh medium. Docetaxel has low solubility in 
phosphate buffered saline (pH 7.4). Therefore, sink conditions were maintained for release 
studies by adding 0.1% w/v Tween 80 in the release medium. The samples were filtered through 
0.45 μm syringe filter before transferred into HPLC vial. The drug content in the samples was 
determined by HPLC (Agilent LC1100, Agilent, Tokyo, Japan) as described in the drug 
encapsulation efficiency determination. The drug release profiles were calculated. 
3.4. Results and Discussion 
3.4.1. Particle size, Polydispersity and zeta potential analysis 
The mean particle size and polydispersity of docetaxel loaded liposomes were shown in Table 
3.2. PCS measurements were undertaken in multimodal analysis to get a true reflection of 
particle size distribution (Muthu and Singh, 2008). The particle size distribution curves for all the 
samples were unimodal. The sizes of docetaxel loaded liposomes prepared by the solvent 
injection method and its population standard deviation were 139.5 ± 1.5, 171.5 ± 1.7, 169.8 ± 
0.44 and 191.7 ± 0.6 nm for batches of the drug loaded, conventional liposomes (DTX-C), TPGS 
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coated liposomes (DTX-TP), the TPGS-COOH coated liposomes (DTX-TP-COOH) and the 
herceptin conjugated liposomes (DTX-TP-HER) respectively.  
Table 3.2: Particle size, polydispersity, zeta potential and encapsulation efficiency of liposomes. 
Batches 
Particle size (nm) 
(mean ± S.Da) 
 
Polydispersity 
(mean ± S.Da) 
Zeta potential (mV) 
(mean ± S.Da) 
Encapsulation 
efficiency (%) 
(mean ± S.Da,b) 
DTX-C 139.5 ±  1.5 0.022 ± 0.005 -2.37 ± 0.28 40.21 ± 0.33 
DTX-TP 171.5 ±  1.7 0.232 ± 0.013 -4.88 ± 0.50 44.65 ± 1.1 
DTX-TP-
COOH 
169.8 ±  0.44 0.125 ± 0.008 -27.4 ± 0.50 49.10 ± 0.55 
DTX-TP-HER 191.7 ± 0.6 0.161 ± 0.005 14.3 ± 0.5 47.86 ± 0.6 
CM6-C 130.4 ± 0.99 0.170 ± 0.003 -3.85 ± 0.960 38.14 ± 0.46 
CM6-TP 162.5 ± 0.4 0.203 ± 0.021 -5.22 ± 0.27 49.95 ± 0.43 
CM6-TP-
COOH 
155.1 ± 0.60 0.200 ± 0.006 -15.06 ± 1.1 55.16 ± 0.71 
CM6-TP-HER 185.6 ± 2.4 0.216 ± 0.029 7.26 ± 0.08 53.34 ± 0.22 
a n=3 
b
 Encapsulation efficiency (%) = (amount of drug or dye loaded in liposomes / amount of drug or dye added during 
fabrication) x 100  
S.D: standard deviation 
DTX: Docetaxel loaded 
CM6: Coumarin-6 loaded 
TP: Liposomes prepared with TPGS 
TP-COOH: Liposomes prepared with TPGS-COOH 
TP-HER: Herceptin conjugated liposomes 
56 
 
The size of the corresponding coumarin-6 loaded liposomes prepared by the solvent injection 
method and its population standard deviation were 130.4 ± 0.99, 162.5±0.4, 155.1±0.60 and 
185.6±2.4 nm for batches of the coumarin-6 loaded, conventional liposomes (CM6-C), TPGS 
coated liposomes (CM6-TP), the TPGS-COOH coated liposomes (CM6-TP-COOH) and the 
herceptin conjugation liposomes (CM6-TP-HER), respectively (Table 3.2). The polydispersity of 
all the liposomes showed quite narrow size distribution, which is nearer to 0.2. The particle size 
results indicate that the herceptin conjugation leads to increase the liposome size as compared to 
TPGS-COOH coated liposomes. This is evident for the conjugation of herceptin over liposomal 
surface. 
The zeta potential of all the liposomes were found to be negatively charged except for the 
herceptin conjugated liposomes. Here, stability of the TPGS-COOH coated liposomes was found 
to be higher than that of the TPGS coated liposomes owing to the better packing of hydrophobic 
group of TPGS-COOH into the bilayer of liposomes. Also the negative charge on the TPGS-
COOH coated liposomes was due to the presence of carboxylic end groups on the surface 
(Kocbek et al., 2007). On the other hand, the herceptin conjugated liposomes also has good 
stability with a positive zeta potential which is attributed to the reduction in the carboxylic group 
of TPGS-COOH and the positive charge of herceptin, thus confirming the conjugation of 
herceptin on the surface. 
3.4.2. Encapsulation efficiency 
The drug encapsulation efficiency (EE) of the docetaxel loaded liposomes were 44.65±1.1, 
49.10±0.55 and 47.86±0.6% for the DTX-TP, DTX-TP-COOH and DTX-TP-HER liposomes, 
respectively. Similarly, dye encapsulation efficiency of the coumarin-6 loaded liposomes were 
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49.95±0.43, 55.16±0.71 and 53.36±0.30 % for the CM6-TP, CM6-TP-COOH and CM6-HER 
liposomes, respectively (Table 3.2). The inclusion of cholesterol to the preparation of liposomes 
provides a condensed effect with the phospholipids improving the stability and the amount of 
docetaxel/dye that could be loaded (Zhao and Feng, 2006). This leads to the reduction in the 
hydrocarbon chain fluidity of the bilayer, keeping the loaded drug/dye intact with them. Coating 
of TPGS and TPGS-COOH further enhances this effect and especially in the later case, where 
the stability increased and may be due to better interaction and packing ability of TPGS-COOH 
with DPPC. This is visualized from the significant increase in the drug/dye encapsulation 
efficiency of TPGS-COOH coated liposomes when compared with the TPGS coated liposomes. 
Surface functionalization should not affect the encapsulation efficiency in general as it would 
decrease the drug diffusion from the liposomes (Sun and Feng, 2009). However the observed EE 
for the herceptin conjugated liposomes was decreased by 2% of the TPGS-COOH liposomes and 
considered not a significant loss. This may occur during the conjugation step. 
3.4.3. Surface morphology 
The AFM image of individual DTX-TP-COOH liposome was shown in Figure 3.2A and 3.2B. A 
smooth surface without any noticeable pinholes or cracks was seen. AFM also revealed that the 
TPGS-COOH coated liposome was spherical in shape of size below 200 nm, which agrees quite 
well with the result measured by PCS. 
Figure 3.3 shows field-emission transmission electron microscope (FETEM) of (A) non-coated 
liposomes in 200 nm scale, (B) an individual TPGS-COOH coated liposome in 200 nm scale, 
which revealed that both the conventional liposomes and TPGS-COOH coated liposome (DTX-
TP-COOH) were spherical in shape (Figure. 3A, 3B). The liposome size as observed by FETEM 
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correlated well with that measured by PCS. Additionally, FETEM images also confirmed the 
presence of TPGS-COOH coating on the liposomes surface. 
 
Figure 3.2A: AFM 2D image of TPGS-COOH coated liposomes showing a particle with 200 nm scale 
 




             
 (A) (B) 
Figure 3.3: TEM image of (A) non-coated liposomes showing particles with 200 nm scale (B) TPGS-
COOH coated liposomes showing a particle with 200 nm scale 
3.4.4. Surface chemistry 
X-ray photoelectron spectroscopy was applied to study the surface chemistry of the docetaxel 
loaded TPGS-COOH coated liposomes with and without herceptin conjugation. The depth to 
which the X-ray can penetrate under the surface is about 5-10 nm and thus the peak obtained is 
for the chemical nature of the surface (Prashant et al., 2010). Figure 3.4 shows the XPS wide 
scan spectrum of the DTX-TP-COOH and DTX-TP-HER liposomes. In the XPS spectrum of 
DTX-TP-COOH, there occurred a high intensity of O 1s signal peak at 285.5 eV binding energy 
position compared to the DTX-TP-HER, which confirmed the presence of oxygen rich carboxyl 
groups on the surface of the liposomes. This clearly depicts the coating of TPGS-COOH on the 
liposomes. Also TPGS-COOH does not contain any nitrogen atoms, while herceptin has such 
atoms in their peptide bond. Therefore nitrogen could be used as a marker to detect the presence 
of herceptin conjugated on the surface of liposomes. From the XPS spectrum of DTX-TP-HER 
60 
 
that there occurred an N 1s signal peak at the 398.7 eV binding energy position and must have 
come from herceptin (Sun and Feng, 2009), which confirmed their successful conjugation on the 
liposomal surface.  
 
Figure 3.4: XPS spectra for the herceptin conjugated and TPGS-COOH coated liposomes. Herceptin 
presence on the surface was confirmed by the presence of N 1s spectra at 397.8eV for conjugated 
liposomes. The TPGS-COOH coating of liposomes was also confirmed by the presence of O 1s 
The C 1s core level spectra of DTX-TP-COOH and DTX-TP-HER liposomes were compared in 
Figure 3.5.  There is a prominent O-C=O peak at 288.4 eV for the DTX-TP-COOH liposomes 
which corresponds to the terminal carboxyl groups present on their surface. This peak decreased 
considerably for the DTX-TP-HER liposomes and the N-C=O peak at 286.6 eV was enhanced 
which contributes for the formation of new amide linkages during herceptin conjugation (Wuang 





Figure 3.5: C 1s core level spectra of (A) DTX-TP-COOH liposomes (B) DTX-TP-HER liposomes 
3.4.5. FTIR and DSC studies 
The FTIR study was used to establish the chemical modifications occurred on the surface of 
liposomes due to herceptin conjugation. Figure 3.6 shows the FTIR spectra of DTX-TP-COOH 
and DTX-TP-HER liposomes. There appeared two characteristic peak at 3300 cm-1 and 1630  
cm-1 for the herceptin conjugated liposomes (DTX-TP-HER) which corresponds to the bonded 
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amide stretching vibrations (Arya et al., 2011), thus confirming the successful conjugation of 
herceptin to the surface of liposome. 
 
Figure 3.6: FTIR spectra for the TPGS-COOH coated liposomes and herceptin conjugated liposomes 
DSC studies were performed for investigating the effect of incorporation of TPGS-COOH and 
docetaxel into the lipid bilayer, which consists of DPPC and cholesterol. Figure 3.7 shows the 
DSC endotherm of DPPC vesicles with cholesterol and DPPC vesicles with cholesterol, 
docetaxel and TPGS-COOH. There occurred a main phase transition temperature (Tm) at 38.2 ̊ C 
for the DPPC+cholesterol vesicles which was well agreed with the literature (Zhao et al., 2007). 
The half height width (HHW) of this peak slightly broadens due to the incorporation of 
cholesterol into the DPPC vesicles. On the other hand there is a strong shift in the Tm around 27  ̊
C for the vesicles with docetaxel and TPGS-COOH, with the peak being broadened. In principle, 
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the HHW of the main phase transition peak will increase with increasing strength of the 
molecular arrangement within the bilayer (Chieng and Chen, 2009). With the addition of TPGS-
COOH and drug, these molecules act as spacers in the lipid bilayer and lower the attractive 
forces between lipid hydrocarbon chains, resulting in a destabilization effect on DPPC vesicles. 
Therefore the hydrocarbon chains can be disturbed more easily by the thermal energy, reaching 
the liquid crystalline phase at a lower temperature (Chieng and Chen, 2009). This confirms the 
incorporation of TPGS-COOH and docetaxel into the DPPC bilayer. 
 
Figure 3.7: DSC thermogram of liposomes prepared with (a) DPPC and cholesterol (b) DPPC, 
cholesterol, docetaxel and TPGS-COOH 
3.4.6. In vitro drug release  
Figure 3.8 shows the accumulated percentage release of docetaxel from the drug loaded TPGS-
coated liposomes (DTX-TP), the herceptin conjugated liposomes (DTX-TP-HER) and 
Taxotere® in phosphate buffered saline (pH 7.4) containing 0.1% w/v Tween 80. There is an 
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initial burst release observed for Taxotere within the first 3 hrs, releasing 80% of the drug. The 
DTX-TP and DTX-TP-HER liposomes however showed exponential release kinetics for more 
than 1 day without any burst release.  
 
Figure 3.8: In vitro drug release from docetaxel loaded liposomes in phosphate buffered saline (pH 7.4).  
Bar represent ± S.D (n = 3) 
After 24 h of dialysis in phosphate buffered saline (pH 7.4), the percentage of docetaxel released 
from the liposomes were 74, 81.25 and 98.97 % for the DTX-TP-HER, DTX-TP and Taxotere® 
respectively (Figure 3.8). The effect of surface modification on the drug release was studied. 
Although there is not much difference in the drug release kinetics of DTX-TP-HER and DTX-
TP, conjugation of herceptin somehow sustained the release of drug from the liposomes. This 
may be due to the better interaction and packing of TPGS-COOH with bilayer and further 
enhanced by the covalent modification by herceptin on the surface. The t50%, at which 50% of the 
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drug encapsulated in the liposomes has released in the phosphate buffered saline (pH 7.4) was 
about 5.32, 3.48 and 1.55 h for the DTX-TP-HER, DTX-TP liposomes and Taxotere® 
respectively. The faster rate of drug releases obtained from the TPGS coated liposomes may be 
explained by the influence of hydrophilic and solubilization property of TPGS on docetaxel (Mu 
et al., 2005; Sheu et al., 2003). 
3.5. Conclusion 
The vitamin E TPGS coated and herceptin conjugated liposomes were prepared by solvent 
injection method and characterized for their size and size distribution, surface charge, surface 
morphology, surface chemistry, drug/dye encapsulation efficiency and in vitro drug release 
profile. Conjugation of herceptin on the liposome surface was confirmed by Fourier transform 
infrared spectroscopy. Molecular arrangement of TPGS-COOH and docetaxel with the lipid 
bilayer was studied using Differential Scanning Calorimetry. The TPGS-COOH coated 
liposomes showed maximum stability and encapsulation efficiency when compared to TPGS 
coated liposomes. In vitro drug release study showed better controlled drug release profile for the 





CHAPTER 4: IN VITRO CELLULAR STUDY OF VITAMIN E TPGS COATED AND 
HERCEPTIN CONJUGATED LIPOSOMES 
 
4.1. Introduction 
Site specific drug delivery to tumor cells achieves better pharmacokinetics profiles, improved 
specificity to certain cancer cell type, increased cellular internalization and intracellular delivery 
and lower systemic toxicity. The key factors involved in tumor targeting by any nanocarriers are 
the use of proper targeting ligands which targets specific cellular markers on the tumor cells, 
delivery of proper therapeutic drug for effective treatment and the mode to deliver the drug to the 
targeted site. Active targeting by ligand conjugation leads to deliver the drug payload specifically 
to tumors cells through enhanced permeation of their blood capillaries and receptor mediated 
endocytosis. In this chapter, in vitro cellular uptake, cell imaging using confocal laser scanning 
microscope and cell viability were studied for herceptin conjugated liposomes and non- 
conjugated liposomes. Active targeting effect was compared in terms of uptake efficiency and 
cell viability. In addition, commercial formulation Taxotere® was also used in cell cytotoxicity 
study to evaluate some of the advantages of using equivalent drug-loaded liposome formulation 
over the clinical formulation. Human breast adenocarcinoma (SK-BR-3) cell line which over 




Phosphate buffered saline (PBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), dimethyl sulfoxide (DMSO), penicillin–streptomycin solution, trypsin-EDTA solution 
and propidium iodide (PI) were purchased from Sigma–Aldrich (St. Louis, MO, USA). Triton X-
100 was provided by USB Corporation (OH, USA), Fetal bovine serum (FBS) and RPMI media 
1640 were purchased from Gibco Life Technologies (AG, Switzerland). SK-BR-3 cells were 
provided by American Type Culture Collection. Clinical formulation Taxotere® was supplied by 
Aventis Pharmaceuticals, USA. All solvents such as ethanol, isopropanol and sodium hydroxide 
(NaOH) were from Sigma-Aldrich. All chemicals were used without further purification. 
Millipore water was prepared by a Milli-Q Plus System (Millipore Corporation, Bredford, USA). 
4.3. Methods 
4.3.1. Cell culture 
In this study, human breast adenocarcinoma SK-BR-3 cell lines  (American Type Culture 
Collection, USA) was cultured in 25 cm2 culture flasks using RPMI supplemented with 10% 
FBS and 1% penicillin-streptomycin and incubated in SANYO CO2  incubator at  37 °C in a 
humidified environment of 5% CO2. The medium was changed every 1 - 2 days until confluence 
was reached. The cells were washed twice with PBS, detached using 0.125% of Trypsin-EDTA 
solution and centrifuged at 2000 rpm for 5 min to recover the cells for further growth or 
experiments. 
4.3.2. Cellular uptake of liposomes 
For quantitative study, confluent SK-BR-3 breast cancer cell line (American Type Culture 
Collection) were harvested with 0.125% Gibco Trypsin-EDTA solution (Invitrogen) and seeded 
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into 96 well assay plates (Corning Incorporated) at 6000 viable cells/well. After the cells reached 
confluence, the cells were incubated with 100 μl  of 5 μg/ml coumarin 6-loaded liposomes 
(targeted and non targeted) in the RPMI 1640 supplemented with 10% Hyclone fetal bovine 
serum (FBS, Thermo Scientific) and 1% Gibco penicillin-streptomycin (Invitrogen) at 37 °C for 
30 min, 1h and 2 h.  At designated time period, the suspension was removed and the wells were 
washed three times with 50 μl cold PBS. After that, 50 μl of 0.5% Triton X-100 in 0.2 N NaOH 
was introduced into each well for cell lysis. The fluorescence intensity of each sample well was 
measured by Tecan microplate reader (GENios) with excitation wavelength at 430 nm and 
emission wavelength at 485 nm. Cellular uptake efficiency was expressed as the percentage of 
cells-associated fluorescence after washing versus the fluorescence present in the feed 
suspension. 
For the qualitative study, confluent SK-BR-3 breast cancer cells  were harvested with 0.125% 
Gibco Trypsin-EDTA solution (Invitrogen) and seeded in LABTEK® cover glass chambers 
(Nagle Nunc®) having DMEM at a concentration of 6000 viable cells/chamber. The cells were 
incubated overnight and were subsequently incubated with coumarin 6-loaded liposomes 
(targeted and non-targeted) in the RPMI 1640 (concentration of 5 μg/ml) at 37 °C.  After 3 h, the 
cells were washed 3 times with cold PBS and fixed by 75% ethanol for 20 min. Then, the cells 
were washed twice with cold PBS. The nuclei were stained by incubating with propidium iodide 
(20 μg/ml) for another 10 min. The cell monolayer was washed three times with PBS and 
observed by confocal laser scanning microscopy (CLSM) (Nikon A1, Nikon Corporation, Japan) 




4.3.3. Cytotoxicity of liposomal formulations 
Cytotoxicity of docetaxel formulated in the drug-loaded liposomes was investigated by the MTT 
assay. 100 μl of SK-BR-3 cells were seeded into 96 well plates (Costar, IL, USA) at the density 
of 5000 viable cells/well with RPMI 1640 and incubated at least overnight to allow cell 
attachment. The spent medium was discarded and the cells were incubated with docetaxel loaded 
targeted and non-targeted liposomes and their cytotoxicity was assessed in comparison with 
Taxotere® at 0.025, 0.25, 2.5 and 25 μg/ml equivalent drug concentration for 24 h. For the 
competitive effect of herceptin, an excess of free herceptin were incubated with the cells 1 hr 
prior to the incubation of liposomal formulations. After 24 h, the medium was removed and the 
wells were washed twice with cold PBS. Following that, 100 μl of MTT solution (0.5mg/ml) 
prepared in the RPMI 1640 was added to each well of the plate. The plates were further 
incubated for 3–4 h in the incubator. Finally, MTT in medium was removed and 50 μl of DMSO 
was added into each well of transformed MTT crystals and the absorbance of the transformed 
MTT solution in the wells was measured at 450 nm wavelength using a microplate reader. Cell 
viability was calculated by the followed equation: 
Cell viability (%) = (ABS of sample/ABS of control) x 100 
where ABS of sample is the absorbance of the transformed MTT in cells incubated with the 
liposomes while the ABS of control is the absorbance of transformed MTT in cells incubated 
with the culture medium only (positive control). IC50, the drug concentration at which 50% of the 
cell population in a designated period was destroyed in comparison with that of the control 




4.4. Results and Discussion 
4.4.1. Cellular Uptake 
The quantitative cellular uptake by SK-BR-3 breast cancer cells after incubation with the 
coumarin-6 loaded TPGS coated liposomes (CM6-TP) – non-targeted, herceptin conjugated 
liposomes (CM6-TP-HER) - targeted and conventional liposomes (CM6-C) - control were 
shown in Figure 4.1. It can be noticed from Figure 8 that there was no trend of general increase 
of liposomes uptake by the cells with the incubation time. The absence of time-dependent 
behavior could be explained by presence of active and maximum endocytosis process within the 
system on or before 30 min (Gupta et al., 2007). Among the three liposome formulations studied, 
it was clearly shown that the cellular uptake of the herceptin conjugated liposomes (CM6-TP-
HER) was significantly higher when compared to the non-targeted liposomes and the control 
formulations (P < 0.05). It was due to the targeting effect of CM6-TP-HER liposomes, which 
enhanced the absorption of the liposomes. 
The confocal images SK-BR-3 cells after incubation with the coumarin-6 loaded TPGS coated 
liposomes (CM6-TP) and the herceptin conjugated liposomes (CM6-TP-HER) were shown in 
Figure 4.2. To better compare the intensity of fluorescence among the cells treated with the two 
types of liposomes, the images were taken under the same imaging parameters such as 
sensitivity, gain, offset, and laser power constant throughout the cell imaging process. It can be 
observed that the green fluorescence in the SK-BR-3 cells from the herceptin conjugated 
liposomes (CM6-TP-HER), was stronger than that of the non-targeted liposomes (the first 
column). More regions in the cytoplasm were stained in green, implying enhanced uptake of the 





Figure 4.1: Cellular uptake efficiency of coumarin-6 loaded liposomes on SK-BR-3 cells after 0.5, 1 and 
3 h incubation 
 
Figure 4.2: Confocal laser scanning microscopy images using SKBR-3 cells after 3 h incubation with the 
fluorescent coumarin-6 loaded (A) TPGS coated liposomes and (B) Herceptin conjugated liposomes. 
Fluorescein isothiocyanate (FITC) channel showing the green fluorescence from liposomes distributed in 
cytoplasm in first column. PI channels showing the red fluorescence from propidium iodide stained nuclei 
in second column and merged channels of FITC and PI in third column. Scale bar = 10 μm 
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4.4.2. Cell Viability 
In vitro cytotoxicity of the docetaxel formulated in the TPGS coated liposomes (DTX-TP) and 
the herceptin conjugated liposomes (DTX-TP-HER) were investigated in comparison with 
Taxotere® at the same equivalent drug concentration on SK-BR-3 breast cells after 24 h 
incubation at 37 °C and the results are shown in Figure 4.3. It is worthy to note that the docetaxel 
loaded liposomes achieved the higher cytotoxicity when compared with commercial Taxotere® 
in all equivalent drug concentration levels applied. This could be due to the effect of controlled 
docetaxel release from the liposomes (Figure 4.3 and Table 4.1). The docetaxel loaded herceptin 
conjugated liposomes (DTX-TP-HER) showed higher cytotoxicity compared with the TPGS 
coated liposomes (Table 4.1). Also, increase in the drug concentration from 0.025 µg/ml to 25 
µg/ml resulted in higher cytotoxicity in presence of endocytic mechanism (Wu et al., 2006). 
 
Figure 4.3: Cytotoxicity of docetaxel loaded liposomes on SK-BR-3 cells for 24 h at 37 °C. Cell viability 
is studied in comparison with commercial formulation Taxotere® 
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Taxotere® DTX-TP DTX-HER + HER     DTX-HER 
24 20.23 ± 1.95 3.74 ± 0.98 0.94 ± 0.37 0.08 ± 0.4 
 
DTX-TP: Docetaxel loaded liposomes prepared with TPGS (non-targeted) 
DTX-TP-HER: Docetaxel loaded Herceptin conjugated liposomes (targeted) 
 
In order to demonstrate the advantages of the docetaxel loaded liposomes, a quantitative index of 
inhibitory concentration, IC50, which is the drug concentration required to induce the death of 
50% cells incubated in a designated period, was determined. For instance, after 24 h incubation, 
IC50 for each of the two types of liposomes, namely the DTX-TP-HER, DTX-TP liposomes vs 
Taxotere® were determined from the cytotoxicity data to be 0.08±0.4, 3.74±0.98, vs. 20.23 ± 
1.95 μg/ml, respectively, which imply that the targeted and non-targeted liposomal formulations 
of docetaxel are 99.65, 81.51 % more efficient than Taxotere® after 24 h treatment, respectively. 
This indicates that in order to kill the same number of cancer cells, the herceptin conjugated 
liposomes (DTX-TP-HER) require much lower drug concentration in comparison with the TPGS 
coated liposomes (Table 4.1). Furthermore the IC50 value for DTX-TP-HER on the cells pre-
incubated with free herceptin was 0.94 ± 0.37 μg/ml which is less cytotoxic when compared to 
DTX-TP-HER. This was possibly due to the competitive effect of herceptin, which reduced the 
binding sites available for the herceptin conjugated liposomes by inhibiting the active receptor 
mediated endocytosis (Gan and Feng, 2010; Wu et al., 2006). However, the cytotoxic effect was 
more when compared to non-targeted formulation (DTX-TP) due to its synergetic effect with 
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free herceptin. Thus the enhanced cytotoxicity of DTX-TP-HER liposomes can be attributed to 
their targeting effect towards the HER-2 receptor on the SK-BR-3 breast cancer cells. Most 
importantly, the herceptin conjugated liposomes could bring high concentration of drug to breast 
cancer cells and reduce the systemic side effects as efficient and cost-effective drug delivery 
system for clinical application.  
4.5. Conclusion 
Cellular uptake and cytotoxicity of the herceptin conjugated liposomes formulated with 
coumarin-6 and docetaxel were investigated in comparison with TPGS coated liposomes and 
clinical Taxotere®. The uptake efficiency of herceptin conjugated liposomes was higher when 
compared to non-conjugated liposomes depicting the targeting effect of former. These 
quantitative results can be confirmed with the images from confocal microscopy. From the IC50 
it was observed that the docetaxel loaded herceptin conjugated liposomes could be 97% more 
efficient than the non-conjugated liposomes after 24 hrs incubation with SK-BR-3 breast cancer 
cells. The lower IC50 in the order of herceptin conjugated liposomes < non-conjugated TPGS 
coated liposomes < Taxotere® further summarized the higher therapeutic efficacy of liposome 










CHAPTER 5: IN VIVO PHARMACOKINETICS 
5.1. Introduction 
The effect and activity of drug loaded liposomes or a commercial drug tested against in vitro 
models may sometimes unable to predict its fate in in vivo systems, not to mention clinical 
cancers. This is due to the much more sophisticated mechanisms that take place within the body 
compared to the simplified in vitro cell line models. Therefore, research involving animals has 
been essential to evaluate the formulation for efficacy and safety before proceeding to human 
trials. In this chapter, in vivo pharmacokinetics for the herceptin conjugated liposomes and 
clinical Taxotere® was carried out on male SD rats to study the long circulation effect and hence 
the drug retention effect in the plasma. Generally the TPGS coated liposomes and PEG coated 
liposomes are said to possess the ‘stealth effect’ which prevents them from capturing by RES 
cells. Here we have used the PEG coated liposomes from our previous work and compared their 




Male Sprague-Dawley (SD) rats of 150-200 gm (or 4-5 weeks old) were supplied by the 
Laboratory Animals Centre of Singapore. They were maintained at the Animal Holding Unit of 
National University of Singapore. The animal caring, handling, husbandry and the protocols 
were approved by the Institutional Animal Care and Use Committee (IACUC), Office of Life 
Sciences, National University of Singapore. The animals were acclimatized at a temperature of 
25 ± 2 ºC and a relative humidity of 50 – 60 % under natural light/dark conditions for 4 – 5 days 
before experiments. 
Saline 0.9% w/v sodium chloride (NaCl) solution was obtained from B.Braun (B.Braun 
Corporation, Germany).  Rats  anaesthesia  (Ketamine  24  mg/ml;  Medetomidine  0.16 mg/ml)  
was  prescribed  by  Animal  Holding  Unit.  All  solvents  including  acetonitrile, methanol  and  
ethyl  acetate  were  of  HPLC  grade.  They were used without further purification. 
5.3. Methods 
The animals were randomly distributed into three groups. Group 1 receiving an intravenous (i.v) 
injection of Taxotere® (n=4). Group 2 receiving an i.v injection of Herceptin conjugated 
liposomes (n=4). Group 3 receiving an i.v injection of PEG coated liposomes (n=4) and this 
formulation was used from our previous study (Muthu et al., 2011) for comparing the long 
circulation characteristics of PEG coated liposomes and herceptin conjugated liposomes. The 
liposome formulations were dispersed in, and Taxotere® was diluted with saline, and 
administered at the same Docetaxel dose of 7 mg/kg body weight. All animals were observed for 
their general condition, clinical signs, and mortality. For Group 1 blood samples were collected 
at 0.5, 2, 4, 8, 12, and 24 and 48h after administration of Taxotere®. For Groups 2 and 3 blood 
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samples were collected at 1, 2, 4, 8, 12, 24, 48h after administration of the liposomal drug 
formulations. Plasma samples were harvested by centrifugation at 11,000 rpm for 10 min and 
stored at - 20 ̊ C for HPLC analysis. Docetaxel in the plasma samples was extracted into 1 ml of 
diethyl ether and was allowed to evaporate in separate tubes. 100 ml of HPLC mobile phase B 
(acetonitrile/methanol/water = 40/5/55 v/v/v) was added to the dried tubes, then vortexed and 
centrifuged at 10 500rpm for 15min. 90 ml of the supernatant was transferred to HPLC vial 
inserts and 50 ml was injected into the column. An elution gradient was applied by increasing the 
proportion of A (acetonitrile/methanol/water = 45/5/50 v/v/v)  from 0 to 100% in 50 min and 
then the system was brought to initial condition of 100% B and equilibrated for 4 min by holding 
at 100% B. The flow rate was 1 ml/min and the total run time was 55 min. The Docetaxel 
concentration in plasma was determined using the standard curve obtained for known 
concentrations of Docetaxel in plasma processed similarly. 
5.4. Results and Discussion 
Figure 5.1 shows the concentration of docetaxel in the plasma versus time curve obtained after 
i.v. injection of Taxotere® and Docetaxel formulated in the herceptin conjugated liposomes 
(DTX-TP-HER) and PEG coated liposomes (DTX-mPEG) to SD rats at the same Docetaxel 
concentration of 7 mg/kg (n=4). The key PK parameters were analyzed using Kinetica 5.0 
software and the results are listed in Table 5.1, which include AUCtot (ng h/ml) – the total area 
under the curve which represents the in vivo therapeutic effects, T1/2 (h) – the half-life of the drug 
in the plasma, i.e. the time at which the drug concentration reached 50% of its peak value in the 
plasma, MRT (h) – the mean residence time of the drug in the plasma, CLtot (L/h/kg) – the total 
clearance of the drug from plasma, Vss (L/kg) - volume of distribution at steady state and relative 
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bioavailability (Fr) –which is defined as the ratio of the AUC values between the drug 
formulation and the commercially available drug injected at the same dose. It was observed from 
the Figure 5.1 that Taxotere® remains in the plasma with shorter circulation time because of its 
short half life. On the other hand, both the herceptin conjugated and PEG coated liposomes 
showed a much longer circulation time. This was due to the so called ‘stealth’ effect of the 
TPGS-COOH and PEG coating respectively. The long circulation characteristics of the 


































Figure 5.1: Pharmacokinetic profiles of Taxotere®, PEG coated liposomes and Herceptin conjugated 
liposomes after intravenous injection in male SD rats at a single equivalent dose of 7 mg/kg. (n=4) 
It can be seen that the half life of DTX-TP-HER liposomes was 43.16 ± 6.26 h and is 1.9 times 
longer than DTX-mPEG liposomes which has 22.62 ± 3.97 h and 10 times longer than 
Taxotere® with 4.74 ± 2.15 h. Also the mean residence time for DTX-TP-HER liposomes was 
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50.56 ± 8.13 h which is 2 times and 15 times longer than PEG coated liposomes and Taxotere® 
respectively. This increased plasma circulation time will provide the herceptin conjugated 
liposomes with a positive and increased targeting effect (Anbharasi et al., 2010). Moreover, the 
total AUC for DTX-TP-HER liposomes was 97740 ng.h/ml, which is 2 fold of DTX-mPEG 
liposomes (48657 ng.h/ml) and 3.5 fold of Taxotere® (28152.1 ng.h/ml) at the same 7mg/kg 
dose of docetaxel. The total clearance of the DTX-TP-HER liposomes was 0.071 ± 0.009 L/h/kg, 
which is at a slower rate as compared with PEG coated liposomes and Taxotere®. This was 
probably due to the effect of TPGS-COOH coating that has slowed down the elimination rate of 
DTX-TP-HER liposomes and prolonged their circulation in the blood (Win and Feng, 2006).  
Table 5.1: Pharmacokinetic parameters of Taxotere®, Herceptin conjugated liposomes and PEG 
coated liposomes after i.v injection at an equivalent dose of 7 mg/kg. 
 PK Parameters Taxotere® DTX-mPEG DTX-TP-HER 
T1/2 (h) 4.74 ± 2.15 22.62 ± 3.97 43.16 ± 6.26 
MRT (h) 3.48 ± 1.88 25.15 ± 4.33 50.56 ± 8.13  
AUC 0-inf (ng.h/ml) 28,152.1 ± 2,650 48,657 ± 3,980 97,740 ± 4,220 
CLtot (L/h/kg) 0.2486 ± 0.09 0.143 ± 0.023 0.071 ± 0.009 
Vss (L/kg) 0.866 ± 0.062 3.618 ± 0.98 3.621 ± 1.25 
Relative Bioavailability ˗ 1.72 fold 3.47 fold 
 
The volume of distribution at steady state was found to be 3.621 ± 1.25 L/kg for DTX-TP-HER 
liposomes which is almost same as the PEG coated liposomes (3.618 ± 0.98 L/kg) and 4 times 
greater than Taxotere® (0.866 ± 0.062 L/kg). The prolonged blood circulation of the herceptin 
conjugated liposomes and PEG coated liposomes as seen from the mean residence time, allows 
them to extravasate from the blood compartment and in turn increases their volume of 
distribution (Dadashzadeh et al., 2008). It has been showed from the table that the relative 
bioavailability of the docetaxel was increased by 3.47 fold by the DTX-TP-HER liposomes and 
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1.72 fold by the DTX-mPEG liposomes. These results have shown that herceptin conjugated 
liposomes has better pharmacokinetic parameters than the PEG coated liposomes and Taxotere® 
and thus provides sustainable and targeted drug delivery. 
5.5. Conclusion 
In this chapter, in vivo pharmacokinetics was studied in male SD rats to evaluate and compare 
the circulation half-life of the drug from the herceptin conjugated liposomes, PEG coated 
liposomes and Taxotere®. It was observed that herceptin conjugated liposomes showed longer 
circulation effect and better pharmacokinetic parameters when compared to the commercial drug 
and PEG coated liposomes. Thus the TPGS coating on the liposomes has a prolonged circulation 












CHAPTER 6: CONCLUSION AND FUTURE WORKS 
6.1. Conclusion 
The main objective of this thesis is to develop a novel vitamin E TPGS coated liposome 
formulation conjugated with herceptin for the targeted and sustained delivery of anticancer drug 
docetaxel. From the results obtained with a series of studies, namely the preparation and 
characterization of liposomes, in vitro cellular uptake and viability as well as in vivo 
pharmacokinetics, herceptin conjugated liposomes has been shown as a promising drug carrier 
for more effective and sustained chemotherapy.  
In Chapter 1, thesis objectives and a general background of the developmental progress of 
liposomes and targeted chemotherapy were provided. Then, Chapter 2 highlighted some facts 
about cancer and its causes, their treatments and problems faced in conventional treatments.  In 
the same chapter, the review on various strategies and nanotechnology applied in developing 
advanced nanocarrier system were also provided. Chapter 3 contained the preparation and 
characterization of vitamin E coated and herceptin conjugated liposomes. The size, shape and 
chemical nature of the liposomes were studied in detail using various state-of-art analytical 
instruments. Conjugation of herceptin on the liposome surface was confirmed by Fourier 
transform infrared spectroscopy and x-ray photoelectron spectroscopy. Molecular arrangement of 
TPGS-COOH and docetaxel with the lipid bilayer was studied using Differential Scanning 
Calorimetry. The TPGS-COOH coated liposomes showed maximum stability and encapsulation 
efficiency when compared to TPGS coated liposomes. In vitro drug release study showed better 
controlled drug release profile for the herceptin conjugated liposomes when compared to non 
conjugated liposomes and Taxotere®.  
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In Chapter 4, the liposomes were further evaluated using human breast cancer cell line SK-BR-3 
as an in vitro model. The uptake efficiency of herceptin conjugated liposomes was higher when 
compared to non-conjugated liposomes depicting the targeting effect of former. These 
quantitative results can be confirmed with the images from confocal microscopy. From the IC50 
it was observed that the docetaxel loaded herceptin conjugated liposomes could be 97% more 
efficient than the non-conjugated liposomes after 24 hrs incubation with SK-BR-3 breast cancer 
cells. The lower IC50 in the order of herceptin conjugated liposomes < non-conjugated TPGS 
coated liposomes < Taxotere® further summarized the higher therapeutic efficacy of liposome 
formulations over the commercial drug.  
Lastly, in vivo pharmacokinetics in Chapter 6 demonstrated the ability of herceptin conjugated 
liposomes to reduce elimination and clearance rates by circumventing the MPS or other efflux 
transport systems in the body. Also the TPGS coating proved much better than the PEG coating 
over the liposomes for enhancing the circulation half-life of the drug. Thus herceptin conjugated 
liposomes showed greater potential and will satisfy the need for sustained and targeted drug 
delivery against human breast cancer. 
6.2. Future works 
Further, some of the future works that may improve the current work were included in the 
following: 
 Development of xenograft tumor models in mice to further evaluate the anti- tumor 
efficacy, side effects and clearance rate of the herceptin conjugated liposomes. 
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 Loading the liposomes with both therapeutic and imaging agents for multi-functional use 
such as cancer diagnosis, imaging and treatment at the same time. Also using HER2 
negative cell line as control to compare the effects of liposomal formulation. 
 Encapsulating the siRNA into the liposomes for their site-specific delivery and treatment. 
 To apply the herceptin conjugated liposomes in clinical phase I trial for further 
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